CN114829357A - 五元杂环氧代羧酸类化合物及其医药用途 - Google Patents
五元杂环氧代羧酸类化合物及其医药用途 Download PDFInfo
- Publication number
- CN114829357A CN114829357A CN202080075621.XA CN202080075621A CN114829357A CN 114829357 A CN114829357 A CN 114829357A CN 202080075621 A CN202080075621 A CN 202080075621A CN 114829357 A CN114829357 A CN 114829357A
- Authority
- CN
- China
- Prior art keywords
- substituted
- unsubstituted
- group
- compound
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 449
- 125000000623 heterocyclic group Chemical group 0.000 title claims description 29
- 239000002253 acid Substances 0.000 title description 15
- -1 heterocyclic oxo carboxylic acid compound Chemical class 0.000 claims abstract description 201
- 238000002360 preparation method Methods 0.000 claims abstract description 135
- 150000003839 salts Chemical class 0.000 claims abstract description 100
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 59
- 201000010099 disease Diseases 0.000 claims abstract description 39
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 37
- 229940002612 prodrug Drugs 0.000 claims abstract description 34
- 239000000651 prodrug Substances 0.000 claims abstract description 34
- 239000012453 solvate Substances 0.000 claims abstract description 33
- 239000003814 drug Substances 0.000 claims abstract description 23
- 239000013078 crystal Substances 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims description 143
- 206010028980 Neoplasm Diseases 0.000 claims description 108
- 229910052736 halogen Inorganic materials 0.000 claims description 88
- 150000002367 halogens Chemical class 0.000 claims description 88
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 81
- 229910052805 deuterium Inorganic materials 0.000 claims description 81
- 238000006467 substitution reaction Methods 0.000 claims description 79
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 68
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 66
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 66
- 201000011510 cancer Diseases 0.000 claims description 61
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 61
- 239000003054 catalyst Substances 0.000 claims description 53
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 52
- 125000005330 8 membered heterocyclic group Chemical group 0.000 claims description 48
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 47
- NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical compound NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 claims description 46
- 125000003368 amide group Chemical group 0.000 claims description 44
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 43
- 125000003118 aryl group Chemical group 0.000 claims description 42
- 125000001072 heteroaryl group Chemical group 0.000 claims description 42
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 31
- 229910052794 bromium Inorganic materials 0.000 claims description 31
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 30
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 30
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 30
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 27
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 26
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 26
- 230000028993 immune response Effects 0.000 claims description 24
- 101710196623 Stimulator of interferon genes protein Proteins 0.000 claims description 20
- 125000003342 alkenyl group Chemical group 0.000 claims description 20
- 229910052717 sulfur Inorganic materials 0.000 claims description 19
- 230000000694 effects Effects 0.000 claims description 18
- 239000003937 drug carrier Substances 0.000 claims description 17
- 125000004432 carbon atom Chemical group C* 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 16
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 15
- 239000004327 boric acid Substances 0.000 claims description 15
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 claims description 15
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 14
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 14
- 229910052757 nitrogen Inorganic materials 0.000 claims description 13
- 229910052760 oxygen Inorganic materials 0.000 claims description 13
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 12
- 125000004442 acylamino group Chemical group 0.000 claims description 11
- 230000008569 process Effects 0.000 claims description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 10
- 206010025323 Lymphomas Diseases 0.000 claims description 10
- 125000004429 atom Chemical group 0.000 claims description 10
- 241000711549 Hepacivirus C Species 0.000 claims description 9
- 206010039491 Sarcoma Diseases 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 8
- 206010006187 Breast cancer Diseases 0.000 claims description 8
- 208000026310 Breast neoplasm Diseases 0.000 claims description 8
- 208000009956 adenocarcinoma Diseases 0.000 claims description 8
- 208000032839 leukemia Diseases 0.000 claims description 8
- 230000003211 malignant effect Effects 0.000 claims description 8
- 125000002560 nitrile group Chemical group 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- 206010009944 Colon cancer Diseases 0.000 claims description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 7
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims description 7
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 7
- 125000005518 carboxamido group Chemical group 0.000 claims description 7
- 208000029742 colonic neoplasm Diseases 0.000 claims description 7
- 208000024348 heart neoplasm Diseases 0.000 claims description 7
- 208000015181 infectious disease Diseases 0.000 claims description 7
- 208000014018 liver neoplasm Diseases 0.000 claims description 7
- 201000005202 lung cancer Diseases 0.000 claims description 7
- 208000020816 lung neoplasm Diseases 0.000 claims description 7
- 206010005949 Bone cancer Diseases 0.000 claims description 6
- 208000018084 Bone neoplasm Diseases 0.000 claims description 6
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 6
- 241000701806 Human papillomavirus Species 0.000 claims description 6
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 6
- 125000003277 amino group Chemical group 0.000 claims description 6
- 210000005095 gastrointestinal system Anatomy 0.000 claims description 6
- 201000010536 head and neck cancer Diseases 0.000 claims description 6
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 6
- 208000027866 inflammatory disease Diseases 0.000 claims description 6
- 208000006178 malignant mesothelioma Diseases 0.000 claims description 6
- 210000004994 reproductive system Anatomy 0.000 claims description 6
- 201000011096 spinal cancer Diseases 0.000 claims description 6
- 208000014618 spinal cord cancer Diseases 0.000 claims description 6
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 6
- 125000000565 sulfonamide group Chemical group 0.000 claims description 6
- 201000002510 thyroid cancer Diseases 0.000 claims description 6
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 5
- 125000004185 ester group Chemical group 0.000 claims description 5
- 201000005787 hematologic cancer Diseases 0.000 claims description 5
- 201000000849 skin cancer Diseases 0.000 claims description 5
- 210000003932 urinary bladder Anatomy 0.000 claims description 5
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 claims description 4
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 241000700605 Viruses Species 0.000 claims description 4
- 230000001580 bacterial effect Effects 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 201000010235 heart cancer Diseases 0.000 claims description 4
- 210000003734 kidney Anatomy 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 201000011216 nasopharynx carcinoma Diseases 0.000 claims description 4
- 125000006708 (C5-C14) heteroaryl group Chemical group 0.000 claims description 3
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 3
- 208000035143 Bacterial infection Diseases 0.000 claims description 3
- 206010004593 Bile duct cancer Diseases 0.000 claims description 3
- 208000015943 Coeliac disease Diseases 0.000 claims description 3
- 201000008808 Fibrosarcoma Diseases 0.000 claims description 3
- 208000021309 Germ cell tumor Diseases 0.000 claims description 3
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 3
- 241000700721 Hepatitis B virus Species 0.000 claims description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
- 208000005615 Interstitial Cystitis Diseases 0.000 claims description 3
- 206010073059 Malignant neoplasm of unknown primary site Diseases 0.000 claims description 3
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 claims description 3
- 241000238711 Pyroglyphidae Species 0.000 claims description 3
- 206010063837 Reperfusion injury Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 229910052770 Uranium Inorganic materials 0.000 claims description 3
- 206010047115 Vasculitis Diseases 0.000 claims description 3
- 208000036142 Viral infection Diseases 0.000 claims description 3
- 206010000496 acne Diseases 0.000 claims description 3
- 208000037883 airway inflammation Diseases 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 3
- 208000013507 chronic prostatitis Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 229940046533 house dust mites Drugs 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 201000007094 prostatitis Diseases 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 201000000306 sarcoidosis Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 230000009385 viral infection Effects 0.000 claims description 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 2
- 229940124530 sulfonamide Drugs 0.000 claims description 2
- 150000003456 sulfonamides Chemical class 0.000 claims description 2
- 206010052399 Neuroendocrine tumour Diseases 0.000 claims 1
- 208000016065 neuroendocrine neoplasm Diseases 0.000 claims 1
- 201000011519 neuroendocrine tumor Diseases 0.000 claims 1
- 102000002227 Interferon Type I Human genes 0.000 abstract description 18
- 108010014726 Interferon Type I Proteins 0.000 abstract description 18
- 229940044665 STING agonist Drugs 0.000 abstract description 11
- 230000028327 secretion Effects 0.000 abstract description 11
- 229940079593 drug Drugs 0.000 abstract description 10
- 238000005481 NMR spectroscopy Methods 0.000 description 276
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 202
- 239000007787 solid Substances 0.000 description 197
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 175
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 94
- 235000002639 sodium chloride Nutrition 0.000 description 94
- 239000000243 solution Substances 0.000 description 93
- 239000000543 intermediate Substances 0.000 description 85
- 239000000203 mixture Substances 0.000 description 75
- 238000006243 chemical reaction Methods 0.000 description 72
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 66
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 62
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 54
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 53
- 239000003208 petroleum Substances 0.000 description 49
- 239000007788 liquid Substances 0.000 description 47
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 44
- 238000004440 column chromatography Methods 0.000 description 41
- SAHIZENKTPRYSN-UHFFFAOYSA-N [2-[3-(phenoxymethyl)phenoxy]-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound O(C1=CC=CC=C1)CC=1C=C(OC2=NC(=CC(=C2)CN)C(F)(F)F)C=CC=1 SAHIZENKTPRYSN-UHFFFAOYSA-N 0.000 description 40
- 210000004027 cell Anatomy 0.000 description 40
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 39
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 36
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 34
- 238000003756 stirring Methods 0.000 description 33
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 31
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 31
- 239000013543 active substance Substances 0.000 description 30
- 239000003921 oil Substances 0.000 description 30
- 235000019198 oils Nutrition 0.000 description 30
- 239000012074 organic phase Substances 0.000 description 28
- 125000005605 benzo group Chemical group 0.000 description 26
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 22
- 229910052786 argon Inorganic materials 0.000 description 22
- 239000002585 base Substances 0.000 description 22
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 21
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 20
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 19
- 208000035475 disorder Diseases 0.000 description 19
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 18
- 230000001939 inductive effect Effects 0.000 description 17
- 239000010410 layer Substances 0.000 description 17
- 230000037361 pathway Effects 0.000 description 16
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 15
- 239000002246 antineoplastic agent Substances 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 15
- 229940127573 compound 38 Drugs 0.000 description 14
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Chemical group C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 14
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 14
- 239000012044 organic layer Substances 0.000 description 14
- 239000002552 dosage form Substances 0.000 description 13
- 239000011541 reaction mixture Substances 0.000 description 13
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 12
- 229960000583 acetic acid Drugs 0.000 description 12
- 230000000259 anti-tumor effect Effects 0.000 description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 12
- 230000002062 proliferating effect Effects 0.000 description 12
- 125000001424 substituent group Chemical group 0.000 description 12
- 239000002671 adjuvant Substances 0.000 description 11
- 239000003112 inhibitor Substances 0.000 description 11
- 239000000546 pharmaceutical excipient Substances 0.000 description 11
- 239000003826 tablet Substances 0.000 description 11
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 10
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 10
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 10
- 125000000217 alkyl group Chemical group 0.000 description 10
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 10
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 9
- IAAQEGBHNXAHBF-UHFFFAOYSA-N 3-thiophen-3-ylthiophene Chemical compound S1C=CC(C2=CSC=C2)=C1 IAAQEGBHNXAHBF-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 125000004122 cyclic group Chemical group 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 102000014150 Interferons Human genes 0.000 description 8
- 108010050904 Interferons Proteins 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- 239000005557 antagonist Substances 0.000 description 8
- 230000005975 antitumor immune response Effects 0.000 description 8
- 239000002775 capsule Substances 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 229940125904 compound 1 Drugs 0.000 description 8
- 125000000392 cycloalkenyl group Chemical group 0.000 description 8
- 230000001419 dependent effect Effects 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 229940079322 interferon Drugs 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 7
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 7
- 229940126253 ADU-S100 Drugs 0.000 description 7
- 206010003571 Astrocytoma Diseases 0.000 description 7
- 108010074708 B7-H1 Antigen Proteins 0.000 description 7
- 229940126657 Compound 17 Drugs 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 7
- ABRVLXLNVJHDRQ-UHFFFAOYSA-N [2-pyridin-3-yl-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound FC(C1=CC(=CC(=N1)C=1C=NC=CC=1)CN)(F)F ABRVLXLNVJHDRQ-UHFFFAOYSA-N 0.000 description 7
- 229940041181 antineoplastic drug Drugs 0.000 description 7
- 229940127089 cytotoxic agent Drugs 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 102000048362 human PDCD1 Human genes 0.000 description 7
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 6
- 125000000979 2-amino-2-oxoethyl group Chemical group [H]C([*])([H])C(=O)N([H])[H] 0.000 description 6
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 6
- 230000000840 anti-viral effect Effects 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 239000012300 argon atmosphere Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 6
- 229910000024 caesium carbonate Inorganic materials 0.000 description 6
- 208000002458 carcinoid tumor Diseases 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- 229940125773 compound 10 Drugs 0.000 description 6
- 229940125877 compound 31 Drugs 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 208000005017 glioblastoma Diseases 0.000 description 6
- 102000048776 human CD274 Human genes 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 6
- PKAHQJNJPDVTDP-UHFFFAOYSA-N methyl cyclopropanecarboxylate Chemical compound COC(=O)C1CC1 PKAHQJNJPDVTDP-UHFFFAOYSA-N 0.000 description 6
- 150000004702 methyl esters Chemical class 0.000 description 6
- 239000006186 oral dosage form Substances 0.000 description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 229960001727 tretinoin Drugs 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 5
- XZOXTYLBVGQTOC-UHFFFAOYSA-N C1=CC=C2C(=C1)C(=CN2)C3=CSC(=C3)C(=O)CC(=O)O Chemical compound C1=CC=C2C(=C1)C(=CN2)C3=CSC(=C3)C(=O)CC(=O)O XZOXTYLBVGQTOC-UHFFFAOYSA-N 0.000 description 5
- OQOUQQXTZRYCHQ-UHFFFAOYSA-N CC(C)CCOC(=O)CCC(=O)C1=CC(=CS1)C2=CNC3=C2C=CC=C3F Chemical compound CC(C)CCOC(=O)CCC(=O)C1=CC(=CS1)C2=CNC3=C2C=CC=C3F OQOUQQXTZRYCHQ-UHFFFAOYSA-N 0.000 description 5
- ZYVIDXKVQFUJJI-UHFFFAOYSA-N COC(=O)CC(=O)C1=CC(=CO1)C2=CNC3=C2C(=CC=C3)F Chemical compound COC(=O)CC(=O)C1=CC(=CO1)C2=CNC3=C2C(=CC=C3)F ZYVIDXKVQFUJJI-UHFFFAOYSA-N 0.000 description 5
- BEUJPPANLAHMGY-UHFFFAOYSA-N COC(=O)CC(=O)C1=CC(=CO1)C2=CNC3=C2C=C(C=C3)F Chemical compound COC(=O)CC(=O)C1=CC(=CO1)C2=CNC3=C2C=C(C=C3)F BEUJPPANLAHMGY-UHFFFAOYSA-N 0.000 description 5
- CJASLJQCIGUBOH-UHFFFAOYSA-N COC(=O)CC(=O)C1=CC(=CO1)C2=CNC3=C2C=CC(=C3)F Chemical compound COC(=O)CC(=O)C1=CC(=CO1)C2=CNC3=C2C=CC(=C3)F CJASLJQCIGUBOH-UHFFFAOYSA-N 0.000 description 5
- IWHGFKMKRPVOFO-UHFFFAOYSA-N COC(=O)CC(=O)C1=CC(=CO1)C2=CNC3=C2C=CC=C3F Chemical compound COC(=O)CC(=O)C1=CC(=CO1)C2=CNC3=C2C=CC=C3F IWHGFKMKRPVOFO-UHFFFAOYSA-N 0.000 description 5
- SIBXOSYXWPCYAO-UHFFFAOYSA-N COC(=O)CC(=O)C1=CC(=CO1)C2=COC3=CC=CC=C32 Chemical compound COC(=O)CC(=O)C1=CC(=CO1)C2=COC3=CC=CC=C32 SIBXOSYXWPCYAO-UHFFFAOYSA-N 0.000 description 5
- PMHCIIVWSYWPHZ-UHFFFAOYSA-N COC(=O)CCC(=O)C1=CC(=CO1)Br Chemical compound COC(=O)CCC(=O)C1=CC(=CO1)Br PMHCIIVWSYWPHZ-UHFFFAOYSA-N 0.000 description 5
- PHJDZJURZUOXBW-UHFFFAOYSA-N COC1=CC2=C(C=C1)NC=C2C3=COC(=C3)C(=O)CC(=O)OC Chemical compound COC1=CC2=C(C=C1)NC=C2C3=COC(=C3)C(=O)CC(=O)OC PHJDZJURZUOXBW-UHFFFAOYSA-N 0.000 description 5
- WZIAPVLNTKZAGR-UHFFFAOYSA-N COC1=CC2=C(C=C1)NC=C2C3=CSC(=C3)C(=O)CC(=O)OC Chemical compound COC1=CC2=C(C=C1)NC=C2C3=CSC(=C3)C(=O)CC(=O)OC WZIAPVLNTKZAGR-UHFFFAOYSA-N 0.000 description 5
- 229940045513 CTLA4 antagonist Drugs 0.000 description 5
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 5
- UNXISIRQWPTTSN-UHFFFAOYSA-N boron;2,3-dimethylbutane-2,3-diol Chemical compound [B].[B].CC(C)(O)C(C)(C)O UNXISIRQWPTTSN-UHFFFAOYSA-N 0.000 description 5
- 208000035269 cancer or benign tumor Diseases 0.000 description 5
- 208000006990 cholangiocarcinoma Diseases 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 210000002865 immune cell Anatomy 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 239000011259 mixed solution Substances 0.000 description 5
- 208000003154 papilloma Diseases 0.000 description 5
- 238000007911 parenteral administration Methods 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 235000011056 potassium acetate Nutrition 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 125000000547 substituted alkyl group Chemical group 0.000 description 5
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 4
- JNUCFXMHRJQKPD-UHFFFAOYSA-N 1-(4,5-dibromothiophen-2-yl)propan-1-one Chemical compound CCC(=O)C1=CC(Br)=C(Br)S1 JNUCFXMHRJQKPD-UHFFFAOYSA-N 0.000 description 4
- IGBZCOWXSCWSHO-UHFFFAOYSA-N 1-(5-bromothiophen-2-yl)ethanone Chemical compound CC(=O)C1=CC=C(Br)S1 IGBZCOWXSCWSHO-UHFFFAOYSA-N 0.000 description 4
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 4
- RSRWVGHLGSSNTK-UHFFFAOYSA-N C1=2C(C3=COC(C(=O)C(C(=O)OCC)(F)F)=C3)=CN(C1=CC=CC=2)C(=O)OC(C)(C)C Chemical compound C1=2C(C3=COC(C(=O)C(C(=O)OCC)(F)F)=C3)=CN(C1=CC=CC=2)C(=O)OC(C)(C)C RSRWVGHLGSSNTK-UHFFFAOYSA-N 0.000 description 4
- NSXGLNQYTMIGRB-UHFFFAOYSA-N C1=CC2=C(C(=C1)F)C(=CN2)C3=COC(=C3)C(=O)CCCC(=O)O Chemical compound C1=CC2=C(C(=C1)F)C(=CN2)C3=COC(=C3)C(=O)CCCC(=O)O NSXGLNQYTMIGRB-UHFFFAOYSA-N 0.000 description 4
- HCXZJUMTBDUJEI-UHFFFAOYSA-N C1=CC2=C(C(=C1)F)C(=CN2)C3=CSC(=C3)C(=O)CC(=O)O Chemical compound C1=CC2=C(C(=C1)F)C(=CN2)C3=CSC(=C3)C(=O)CC(=O)O HCXZJUMTBDUJEI-UHFFFAOYSA-N 0.000 description 4
- SNSQVVDVMSLVHD-UHFFFAOYSA-N C1=CC2=C(C(=C1)F)C(=CN2)C3=CSC(=C3)C(=O)CCCC(=O)O Chemical compound C1=CC2=C(C(=C1)F)C(=CN2)C3=CSC(=C3)C(=O)CCCC(=O)O SNSQVVDVMSLVHD-UHFFFAOYSA-N 0.000 description 4
- LHPPTJZEFDNAIZ-UHFFFAOYSA-N C1=CC2=C(C(=C1)F)NC=C2C3=COC(=C3)C(=O)C(C(=O)O)(F)F Chemical compound C1=CC2=C(C(=C1)F)NC=C2C3=COC(=C3)C(=O)C(C(=O)O)(F)F LHPPTJZEFDNAIZ-UHFFFAOYSA-N 0.000 description 4
- NCCDHQSEPQWRRF-UHFFFAOYSA-N C1=CC2=C(C(=C1)F)NC=C2C3=COC(=C3)C(=O)CCCC(=O)O Chemical compound C1=CC2=C(C(=C1)F)NC=C2C3=COC(=C3)C(=O)CCCC(=O)O NCCDHQSEPQWRRF-UHFFFAOYSA-N 0.000 description 4
- RGEMYLAXKHWZAK-UHFFFAOYSA-N C1=CC2=C(C(=C1)F)NC=C2C3=CSC(=C3)C(=O)C(C(=O)O)(F)F Chemical compound C1=CC2=C(C(=C1)F)NC=C2C3=CSC(=C3)C(=O)C(C(=O)O)(F)F RGEMYLAXKHWZAK-UHFFFAOYSA-N 0.000 description 4
- FCWYNYKVHOBYRW-UHFFFAOYSA-N C1=CC2=C(C(=C1)F)NC=C2C3=CSC(=C3)C(=O)CC(=O)O Chemical compound C1=CC2=C(C(=C1)F)NC=C2C3=CSC(=C3)C(=O)CC(=O)O FCWYNYKVHOBYRW-UHFFFAOYSA-N 0.000 description 4
- FWLXPPPYWXWGME-UHFFFAOYSA-N C1=CC2=C(C(=C1)F)NC=C2C3=CSC(=C3)C(=O)CCCC(=O)O Chemical compound C1=CC2=C(C(=C1)F)NC=C2C3=CSC(=C3)C(=O)CCCC(=O)O FWLXPPPYWXWGME-UHFFFAOYSA-N 0.000 description 4
- LJLNCVMFOJTYOM-UHFFFAOYSA-N C1=CC2=C(C=C1F)C(=CN2)C3=COC(=C3)C(=O)CCCC(=O)O Chemical compound C1=CC2=C(C=C1F)C(=CN2)C3=COC(=C3)C(=O)CCCC(=O)O LJLNCVMFOJTYOM-UHFFFAOYSA-N 0.000 description 4
- ACSBIZMLYRMKOR-UHFFFAOYSA-N C1=CC2=C(C=C1F)C(=CN2)C3=CSC(=C3)C(=O)CC(=O)O Chemical compound C1=CC2=C(C=C1F)C(=CN2)C3=CSC(=C3)C(=O)CC(=O)O ACSBIZMLYRMKOR-UHFFFAOYSA-N 0.000 description 4
- YTUZUEGLFKUVNW-UHFFFAOYSA-N C1=CC2=C(C=C1F)C(=CN2)C3=CSC(=C3)C(=O)CCCC(=O)O Chemical compound C1=CC2=C(C=C1F)C(=CN2)C3=CSC(=C3)C(=O)CCCC(=O)O YTUZUEGLFKUVNW-UHFFFAOYSA-N 0.000 description 4
- XPQNKCFOPWMALD-UHFFFAOYSA-N C1=CC2=C(C=C1F)NC=C2C3=COC(=C3)C(=O)C(C(=O)O)(F)F Chemical compound C1=CC2=C(C=C1F)NC=C2C3=COC(=C3)C(=O)C(C(=O)O)(F)F XPQNKCFOPWMALD-UHFFFAOYSA-N 0.000 description 4
- YSXVVHURZAKQFW-UHFFFAOYSA-N C1=CC2=C(C=C1F)NC=C2C3=COC(=C3)C(=O)CCCC(=O)O Chemical compound C1=CC2=C(C=C1F)NC=C2C3=COC(=C3)C(=O)CCCC(=O)O YSXVVHURZAKQFW-UHFFFAOYSA-N 0.000 description 4
- CFFLSDKYXGDWPN-UHFFFAOYSA-N C1=CC2=C(C=C1F)NC=C2C3=CSC(=C3)C(=O)C(C(=O)O)(F)F Chemical compound C1=CC2=C(C=C1F)NC=C2C3=CSC(=C3)C(=O)C(C(=O)O)(F)F CFFLSDKYXGDWPN-UHFFFAOYSA-N 0.000 description 4
- NGUVWACMRRLUPO-UHFFFAOYSA-N C1=CC2=C(C=C1F)NC=C2C3=CSC(=C3)C(=O)CC(=O)O Chemical compound C1=CC2=C(C=C1F)NC=C2C3=CSC(=C3)C(=O)CC(=O)O NGUVWACMRRLUPO-UHFFFAOYSA-N 0.000 description 4
- CIDQQTMWJUXSAF-UHFFFAOYSA-N C1=CC2=C(C=C1F)NC=C2C3=CSC(=C3)C(=O)CCCC(=O)O Chemical compound C1=CC2=C(C=C1F)NC=C2C3=CSC(=C3)C(=O)CCCC(=O)O CIDQQTMWJUXSAF-UHFFFAOYSA-N 0.000 description 4
- IDKCFDJWHQXRES-UHFFFAOYSA-N C1=CC=C2C(=C1)C(=CN2)C3=COC(=C3)C(=O)C(C(=O)O)(F)F Chemical compound C1=CC=C2C(=C1)C(=CN2)C3=COC(=C3)C(=O)C(C(=O)O)(F)F IDKCFDJWHQXRES-UHFFFAOYSA-N 0.000 description 4
- ZXEGKTASKYZDMY-UHFFFAOYSA-N C1=CC=C2C(=C1)C(=CN2)C3=CSC(=C3)C(=O)CCC(=O)OC4=CN=CC=C4 Chemical compound C1=CC=C2C(=C1)C(=CN2)C3=CSC(=C3)C(=O)CCC(=O)OC4=CN=CC=C4 ZXEGKTASKYZDMY-UHFFFAOYSA-N 0.000 description 4
- BCPHHYXSMMCSMA-UHFFFAOYSA-N C1=CC=C2C(=C1)C(=CN2)C3=CSC(=C3)C(=O)CCCC(=O)O Chemical compound C1=CC=C2C(=C1)C(=CN2)C3=CSC(=C3)C(=O)CCCC(=O)O BCPHHYXSMMCSMA-UHFFFAOYSA-N 0.000 description 4
- AUAVDALWRCUKFP-UHFFFAOYSA-N C1=CC=C2C(=C1)C(=CN2)C3=CSC(=C3)C(=O)CCCCC(=O)O Chemical compound C1=CC=C2C(=C1)C(=CN2)C3=CSC(=C3)C(=O)CCCCC(=O)O AUAVDALWRCUKFP-UHFFFAOYSA-N 0.000 description 4
- NRFFLQWGKASTMS-UHFFFAOYSA-N C1CC1(C(=O)C2=CC(=CS2)C3=CNC4=CC=CC=C43)C(=O)O Chemical compound C1CC1(C(=O)C2=CC(=CS2)C3=CNC4=CC=CC=C43)C(=O)O NRFFLQWGKASTMS-UHFFFAOYSA-N 0.000 description 4
- ZOCDVNKLJFEZIK-UHFFFAOYSA-N C1CCC2=C(C1)C=CC(=C2)OC(=O)CCC(=O)C3=CC(=CS3)C4=CNC5=CC=CC=C54 Chemical compound C1CCC2=C(C1)C=CC(=C2)OC(=O)CCC(=O)C3=CC(=CS3)C4=CNC5=CC=CC=C54 ZOCDVNKLJFEZIK-UHFFFAOYSA-N 0.000 description 4
- APLQMBFBWFBADB-UHFFFAOYSA-N CC(C(=O)C1=CC(=C(S1)Br)Br)C(=O)OC Chemical compound CC(C(=O)C1=CC(=C(S1)Br)Br)C(=O)OC APLQMBFBWFBADB-UHFFFAOYSA-N 0.000 description 4
- GNOQEOFTUNOBJO-UHFFFAOYSA-N CC(C(=O)C1=CC(=CS1)C2=CN(C3=C2C=CC=C3F)C(=O)OC(C)(C)C)C(=O)OC Chemical compound CC(C(=O)C1=CC(=CS1)C2=CN(C3=C2C=CC=C3F)C(=O)OC(C)(C)C)C(=O)OC GNOQEOFTUNOBJO-UHFFFAOYSA-N 0.000 description 4
- WGUJWODEIOEBQB-UHFFFAOYSA-N CC(C(=O)C1=CC(=CS1)C2=CNC3=C2C=CC=C3F)C(=O)O Chemical compound CC(C(=O)C1=CC(=CS1)C2=CNC3=C2C=CC=C3F)C(=O)O WGUJWODEIOEBQB-UHFFFAOYSA-N 0.000 description 4
- MQMXYQPUASFEHW-UHFFFAOYSA-N CC(C)(C)OC(=O)N1C=C(C2=C1C(=CC=C2)F)C3=COC(=C3)C=O Chemical compound CC(C)(C)OC(=O)N1C=C(C2=C1C(=CC=C2)F)C3=COC(=C3)C=O MQMXYQPUASFEHW-UHFFFAOYSA-N 0.000 description 4
- OIWHHVVNWFNENH-UHFFFAOYSA-N CC(C)(C)OC(=O)N1C=C(C2=C1C(=CC=C2)F)C3=CSC(=C3)C(=O)CC(=O)OC Chemical compound CC(C)(C)OC(=O)N1C=C(C2=C1C(=CC=C2)F)C3=CSC(=C3)C(=O)CC(=O)OC OIWHHVVNWFNENH-UHFFFAOYSA-N 0.000 description 4
- IBCGBDAZPBDFIO-UHFFFAOYSA-N CC(C)(C)OC(=O)N1C=C(C2=C1C=C(C=C2)F)C3=COC(=C3)C=O Chemical compound CC(C)(C)OC(=O)N1C=C(C2=C1C=C(C=C2)F)C3=COC(=C3)C=O IBCGBDAZPBDFIO-UHFFFAOYSA-N 0.000 description 4
- CIRNUXQKWLMELN-UHFFFAOYSA-N CC(C)(C)OC(=O)N1C=C(C2=C1C=C(C=C2)F)C3=CSC(=C3)C(=O)CC(=O)OC Chemical compound CC(C)(C)OC(=O)N1C=C(C2=C1C=C(C=C2)F)C3=CSC(=C3)C(=O)CC(=O)OC CIRNUXQKWLMELN-UHFFFAOYSA-N 0.000 description 4
- NIUWMYFKTGDCBB-UHFFFAOYSA-N CC(C)(C)OC(=O)N1C=C(C2=C1C=C(C=C2)F)C3=CSC(=C3)C=O Chemical compound CC(C)(C)OC(=O)N1C=C(C2=C1C=C(C=C2)F)C3=CSC(=C3)C=O NIUWMYFKTGDCBB-UHFFFAOYSA-N 0.000 description 4
- OAUKEUPRZYHPBV-UHFFFAOYSA-N CC(C)(C)OC(=O)N1C=C(C2=C1C=CC(=C2)F)C3=CSC(=C3)C(=O)CC(=O)OC Chemical compound CC(C)(C)OC(=O)N1C=C(C2=C1C=CC(=C2)F)C3=CSC(=C3)C(=O)CC(=O)OC OAUKEUPRZYHPBV-UHFFFAOYSA-N 0.000 description 4
- QFJFRNFPNOOARS-UHFFFAOYSA-N CC(C)(C)OC(=O)N1C=C(C2=C1C=CC=C2F)C3=CSC(=C3)C(=O)CC(=O)OC Chemical compound CC(C)(C)OC(=O)N1C=C(C2=C1C=CC=C2F)C3=CSC(=C3)C(=O)CC(=O)OC QFJFRNFPNOOARS-UHFFFAOYSA-N 0.000 description 4
- GDCRPUKICVESJN-UHFFFAOYSA-N CC(C)(C)OC(=O)N1C=C(C2=CC=CC=C21)C3=COC(=C3)C=O Chemical compound CC(C)(C)OC(=O)N1C=C(C2=CC=CC=C21)C3=COC(=C3)C=O GDCRPUKICVESJN-UHFFFAOYSA-N 0.000 description 4
- FBYPAIUKTODADI-UHFFFAOYSA-N CCOC(=O)C(C(=O)C1=CC(=CO1)C2=CN(C3=C2C=CC(=C3)F)C(=O)OC(C)(C)C)(F)F Chemical compound CCOC(=O)C(C(=O)C1=CC(=CO1)C2=CN(C3=C2C=CC(=C3)F)C(=O)OC(C)(C)C)(F)F FBYPAIUKTODADI-UHFFFAOYSA-N 0.000 description 4
- RIEVBZNWBWSKBJ-UHFFFAOYSA-N CCOC(=O)C(C(=O)C1=CC(=CO1)C2=CN(C3=C2C=CC=C3F)C(=O)OC(C)(C)C)(F)F Chemical compound CCOC(=O)C(C(=O)C1=CC(=CO1)C2=CN(C3=C2C=CC=C3F)C(=O)OC(C)(C)C)(F)F RIEVBZNWBWSKBJ-UHFFFAOYSA-N 0.000 description 4
- PGHVGZFVIAJIRI-UHFFFAOYSA-N CCOC(=O)C(C(=O)C1=CC(=CS1)C2=CN(C3=C2C=CC(=C3)F)C(=O)OC(C)(C)C)(F)F Chemical compound CCOC(=O)C(C(=O)C1=CC(=CS1)C2=CN(C3=C2C=CC(=C3)F)C(=O)OC(C)(C)C)(F)F PGHVGZFVIAJIRI-UHFFFAOYSA-N 0.000 description 4
- PDAXYKBPWWTFHZ-UHFFFAOYSA-N CCOC(=O)C(C(C1=CC(=CO1)C2=CN(C3=C2C=CC(=C3)F)C(=O)OC(C)(C)C)O)(F)F Chemical compound CCOC(=O)C(C(C1=CC(=CO1)C2=CN(C3=C2C=CC(=C3)F)C(=O)OC(C)(C)C)O)(F)F PDAXYKBPWWTFHZ-UHFFFAOYSA-N 0.000 description 4
- MBPVJYNTCOQATP-UHFFFAOYSA-N CCOC(=O)C(C(C1=CC(=CO1)C2=CN(C3=C2C=CC=C3F)C(=O)OC(C)(C)C)O)(F)F Chemical compound CCOC(=O)C(C(C1=CC(=CO1)C2=CN(C3=C2C=CC=C3F)C(=O)OC(C)(C)C)O)(F)F MBPVJYNTCOQATP-UHFFFAOYSA-N 0.000 description 4
- NPEJVBPMCASPLD-UHFFFAOYSA-N CCOC(=O)C(C(C1=CC(=CO1)C2=CN(C3=CC=CC=C32)C(=O)OC(C)(C)C)O)(F)F Chemical compound CCOC(=O)C(C(C1=CC(=CO1)C2=CN(C3=CC=CC=C32)C(=O)OC(C)(C)C)O)(F)F NPEJVBPMCASPLD-UHFFFAOYSA-N 0.000 description 4
- AKMDMCWEJGDCMT-UHFFFAOYSA-N CCOC(=O)C(C(C1=CC(=CS1)C2=CN(C3=C2C=CC(=C3)F)C(=O)OC(C)(C)C)O)(F)F Chemical compound CCOC(=O)C(C(C1=CC(=CS1)C2=CN(C3=C2C=CC(=C3)F)C(=O)OC(C)(C)C)O)(F)F AKMDMCWEJGDCMT-UHFFFAOYSA-N 0.000 description 4
- HJLMZBPGEXEAAT-UHFFFAOYSA-N COC(=O)CCC(=O)c1cc(Br)cs1 Chemical compound COC(=O)CCC(=O)c1cc(Br)cs1 HJLMZBPGEXEAAT-UHFFFAOYSA-N 0.000 description 4
- OSLNEVJXRQCYKS-UHFFFAOYSA-N COC(=O)CCC(C1=CC(=CS1)C2=CNC3=C2C=CC=C3F)O Chemical compound COC(=O)CCC(C1=CC(=CS1)C2=CNC3=C2C=CC=C3F)O OSLNEVJXRQCYKS-UHFFFAOYSA-N 0.000 description 4
- YIBJJFGQVNLRGO-UHFFFAOYSA-N COC(=O)CCCC(=O)C1=CC(=C(O1)Br)Br Chemical compound COC(=O)CCCC(=O)C1=CC(=C(O1)Br)Br YIBJJFGQVNLRGO-UHFFFAOYSA-N 0.000 description 4
- FDKIGNWEGDUYMO-UHFFFAOYSA-N COC(=O)CCCC(=O)C1=CC(=C(S1)Br)Br Chemical compound COC(=O)CCCC(=O)C1=CC(=C(S1)Br)Br FDKIGNWEGDUYMO-UHFFFAOYSA-N 0.000 description 4
- UQZDBKMLBYJZKJ-UHFFFAOYSA-N COC(=O)CCCC(=O)C1=CC(=CO1)Br Chemical compound COC(=O)CCCC(=O)C1=CC(=CO1)Br UQZDBKMLBYJZKJ-UHFFFAOYSA-N 0.000 description 4
- YOFCTZOJDXMHJA-UHFFFAOYSA-N COC(=O)CCCCC(=O)C1=CC(=C(S1)Br)Br Chemical compound COC(=O)CCCCC(=O)C1=CC(=C(S1)Br)Br YOFCTZOJDXMHJA-UHFFFAOYSA-N 0.000 description 4
- LJNUDBGZPPZBPS-UHFFFAOYSA-N COC(C(C=O)C1=CC(C2=CC=CC=C2)=CS1)=O Chemical compound COC(C(C=O)C1=CC(C2=CC=CC=C2)=CS1)=O LJNUDBGZPPZBPS-UHFFFAOYSA-N 0.000 description 4
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 4
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 4
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 4
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
- 239000012269 PD-1/PD-L1 inhibitor Substances 0.000 description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 4
- 229940100198 alkylating agent Drugs 0.000 description 4
- 239000002168 alkylating agent Substances 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 230000000340 anti-metabolite Effects 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 210000000612 antigen-presenting cell Anatomy 0.000 description 4
- 229940100197 antimetabolite Drugs 0.000 description 4
- 239000002256 antimetabolite Substances 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 150000002431 hydrogen Chemical class 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000015788 innate immune response Effects 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- YVARZQNTRVLUJR-UHFFFAOYSA-N methyl 3-(4-bromothiophen-2-yl)-2-methyl-3-oxopropanoate Chemical compound COC(=O)C(C)C(=O)C1=CC(Br)=CS1 YVARZQNTRVLUJR-UHFFFAOYSA-N 0.000 description 4
- LXADGPLPPGQZNI-UHFFFAOYSA-N methyl 3-(5-bromothiophen-2-yl)-3-oxopropanoate Chemical compound COC(=O)CC(=O)C1=CC=C(Br)S1 LXADGPLPPGQZNI-UHFFFAOYSA-N 0.000 description 4
- WSXFARNGZQRGFM-UHFFFAOYSA-N methyl 5-(4-bromothiophen-2-yl)-5-oxopentanoate Chemical compound COC(=O)CCCC(=O)C1=CC(=CS1)Br WSXFARNGZQRGFM-UHFFFAOYSA-N 0.000 description 4
- AMPCATHXOHSUCT-UHFFFAOYSA-N methyl 6-(4-bromothiophen-2-yl)-6-oxohexanoate Chemical compound COC(=O)CCCCC(=O)C1=CC(=CS1)Br AMPCATHXOHSUCT-UHFFFAOYSA-N 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 230000000955 neuroendocrine Effects 0.000 description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 4
- 229940121653 pd-1/pd-l1 inhibitor Drugs 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 125000003107 substituted aryl group Chemical group 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 3
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- HLLGVBMZPQPUPZ-UHFFFAOYSA-N 2-(2,6-dibromophenyl)acetaldehyde Chemical compound BrC1=CC=CC(Br)=C1CC=O HLLGVBMZPQPUPZ-UHFFFAOYSA-N 0.000 description 3
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 3
- MIGFXCFLPWYSJA-UHFFFAOYSA-N 3,4-dibromofuran-2-carbaldehyde Chemical compound BrC1=COC(C=O)=C1Br MIGFXCFLPWYSJA-UHFFFAOYSA-N 0.000 description 3
- QFWZYCWYNOMSQC-UHFFFAOYSA-N 3-bromo-6-fluoro-1h-indole Chemical compound FC1=CC=C2C(Br)=CNC2=C1 QFWZYCWYNOMSQC-UHFFFAOYSA-N 0.000 description 3
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 3
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 3
- 102100037435 Antiviral innate immune response receptor RIG-I Human genes 0.000 description 3
- 108010024976 Asparaginase Proteins 0.000 description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 3
- GXNLDHQUYBGIFK-UHFFFAOYSA-N C1=2C(C3=CSC(=C3)C(=O)C(C(=O)OCC)(F)F)=CN(C1=CC=CC=2)C(=O)OC(C)(C)C Chemical compound C1=2C(C3=CSC(=C3)C(=O)C(C(=O)OCC)(F)F)=CN(C1=CC=CC=2)C(=O)OC(C)(C)C GXNLDHQUYBGIFK-UHFFFAOYSA-N 0.000 description 3
- WGRUULFNYIZGJM-UHFFFAOYSA-N C1=CC2=C(C(=C1)F)NC=C2C3=CSC(=C3)C(CCC(=O)O)O Chemical compound C1=CC2=C(C(=C1)F)NC=C2C3=CSC(=C3)C(CCC(=O)O)O WGRUULFNYIZGJM-UHFFFAOYSA-N 0.000 description 3
- QWXJFCMMSUHVIA-UHFFFAOYSA-N C1=CC2=C(C=C1F)OC=C2Br Chemical compound C1=CC2=C(C=C1F)OC=C2Br QWXJFCMMSUHVIA-UHFFFAOYSA-N 0.000 description 3
- DXCKJIITCGJSRW-UHFFFAOYSA-N C1=CC=C(C=C1)COC(=O)CCC(=O)C2=CC(=CS2)C3=CNC4=CC=CC=C43 Chemical compound C1=CC=C(C=C1)COC(=O)CCC(=O)C2=CC(=CS2)C3=CNC4=CC=CC=C43 DXCKJIITCGJSRW-UHFFFAOYSA-N 0.000 description 3
- XEDXKIRXWCXYKM-UHFFFAOYSA-N C1=CC=C2C(=C1)C(=CN2)C3=COC(=C3)C(=O)CCC(=O)O Chemical compound C1=CC=C2C(=C1)C(=CN2)C3=COC(=C3)C(=O)CCC(=O)O XEDXKIRXWCXYKM-UHFFFAOYSA-N 0.000 description 3
- JEWLVFJMVGOAJU-UHFFFAOYSA-N C1=CC=C2C(=C1)C(=CN2)C3=CSC(=C3)C(=O)CCC(=O)O Chemical compound C1=CC=C2C(=C1)C(=CN2)C3=CSC(=C3)C(=O)CCC(=O)O JEWLVFJMVGOAJU-UHFFFAOYSA-N 0.000 description 3
- LWJRMQRXGGJGEK-UHFFFAOYSA-N C1=CC=C2C(=C1)C(=CO2)C3=COC(=C3)C=O Chemical compound C1=CC=C2C(=C1)C(=CO2)C3=COC(=C3)C=O LWJRMQRXGGJGEK-UHFFFAOYSA-N 0.000 description 3
- IHMNYJULBAEICA-UHFFFAOYSA-N C1CCC(CC1)OC(=O)CCC(=O)C2=CC(=CS2)C3=CNC4=CC=CC=C43 Chemical compound C1CCC(CC1)OC(=O)CCC(=O)C2=CC(=CS2)C3=CNC4=CC=CC=C43 IHMNYJULBAEICA-UHFFFAOYSA-N 0.000 description 3
- ZKGMXUVFAXZPJB-UHFFFAOYSA-N C1COCCC1OC(=O)CCC(=O)C2=CC(=CO2)C3=CNC4=CC=CC=C43 Chemical compound C1COCCC1OC(=O)CCC(=O)C2=CC(=CO2)C3=CNC4=CC=CC=C43 ZKGMXUVFAXZPJB-UHFFFAOYSA-N 0.000 description 3
- OHHISXXTCMLBHO-UHFFFAOYSA-N CCOC(=O)C(C(C1=CC(=CS1)C2=CN(C3=CC=CC=C32)C(=O)OC(C)(C)C)O)(F)F Chemical compound CCOC(=O)C(C(C1=CC(=CS1)C2=CN(C3=CC=CC=C32)C(=O)OC(C)(C)C)O)(F)F OHHISXXTCMLBHO-UHFFFAOYSA-N 0.000 description 3
- WUDXCEIXVZUBHX-UHFFFAOYSA-N COC(=O)C(C(=O)C1=CC(=CS1)C2=CNC3=C2C=CC=C3F)(F)F Chemical compound COC(=O)C(C(=O)C1=CC(=CS1)C2=CNC3=C2C=CC=C3F)(F)F WUDXCEIXVZUBHX-UHFFFAOYSA-N 0.000 description 3
- JMLPQRRXGPQLPX-UHFFFAOYSA-N COC(=O)CC(=O)C1=CC(=CO1)C2=C3C=COC3=CC=C2 Chemical compound COC(=O)CC(=O)C1=CC(=CO1)C2=C3C=COC3=CC=C2 JMLPQRRXGPQLPX-UHFFFAOYSA-N 0.000 description 3
- MBIXCWXVLKQIKP-UHFFFAOYSA-N COC(=O)CC(=O)C1=CC(=CO1)C2=CC3=C(C=C2)C=CO3 Chemical compound COC(=O)CC(=O)C1=CC(=CO1)C2=CC3=C(C=C2)C=CO3 MBIXCWXVLKQIKP-UHFFFAOYSA-N 0.000 description 3
- MMEMTFKMDHZJTG-UHFFFAOYSA-N COC(=O)CC(=O)C1=CC(=CO1)C2=CC3=C(C=C2)OC=C3 Chemical compound COC(=O)CC(=O)C1=CC(=CO1)C2=CC3=C(C=C2)OC=C3 MMEMTFKMDHZJTG-UHFFFAOYSA-N 0.000 description 3
- YSPYCBBNZRCFGU-UHFFFAOYSA-N COC(=O)CC(=O)C1=CC(=CO1)C2=CC3=CC=CC=C3O2 Chemical compound COC(=O)CC(=O)C1=CC(=CO1)C2=CC3=CC=CC=C3O2 YSPYCBBNZRCFGU-UHFFFAOYSA-N 0.000 description 3
- MYZJTKUYKXFTBT-UHFFFAOYSA-N COC(=O)CC(=O)C1=CC(=CS1)C2=CC=CC3=C2OC=C3 Chemical compound COC(=O)CC(=O)C1=CC(=CS1)C2=CC=CC3=C2OC=C3 MYZJTKUYKXFTBT-UHFFFAOYSA-N 0.000 description 3
- AEUGQXKLMIJUKZ-UHFFFAOYSA-N COC(=O)CC(=O)C1=CC(=CS1)C2=CC=CC3=CC=CC=C32 Chemical compound COC(=O)CC(=O)C1=CC(=CS1)C2=CC=CC3=CC=CC=C32 AEUGQXKLMIJUKZ-UHFFFAOYSA-N 0.000 description 3
- MKZCKTCPHAYJRN-UHFFFAOYSA-N COC(=O)CC(=O)C1=CC(=CS1)C2=CNC3=C2C(=CC=C3)F Chemical compound COC(=O)CC(=O)C1=CC(=CS1)C2=CNC3=C2C(=CC=C3)F MKZCKTCPHAYJRN-UHFFFAOYSA-N 0.000 description 3
- QUPWPIQRTJDVPL-UHFFFAOYSA-N COC(=O)CC(=O)C1=CC(=CS1)C2=CNC3=C2C=C(C=C3)F Chemical compound COC(=O)CC(=O)C1=CC(=CS1)C2=CNC3=C2C=C(C=C3)F QUPWPIQRTJDVPL-UHFFFAOYSA-N 0.000 description 3
- BITHXQHWGNMUQL-UHFFFAOYSA-N COC(=O)CC(=O)C1=CC(=CS1)C2=CNC3=C2C=CC(=C3)F Chemical compound COC(=O)CC(=O)C1=CC(=CS1)C2=CNC3=C2C=CC(=C3)F BITHXQHWGNMUQL-UHFFFAOYSA-N 0.000 description 3
- MPBUMTNCQATWDX-UHFFFAOYSA-N COC(=O)CC(=O)C1=CC(=CS1)C2=CNC3=C2C=CC=C3F Chemical compound COC(=O)CC(=O)C1=CC(=CS1)C2=CNC3=C2C=CC=C3F MPBUMTNCQATWDX-UHFFFAOYSA-N 0.000 description 3
- WRFVPKFSSLOAFP-UHFFFAOYSA-N COC(=O)CC(=O)C1=CC(=CS1)C2=CNC3=CC=CC=C32 Chemical compound COC(=O)CC(=O)C1=CC(=CS1)C2=CNC3=CC=CC=C32 WRFVPKFSSLOAFP-UHFFFAOYSA-N 0.000 description 3
- AAWJSDFZSZAIBG-UHFFFAOYSA-N COC(=O)CC(=O)C1=CC=C(S1)C2=CSC3=CC=CC=C32 Chemical compound COC(=O)CC(=O)C1=CC=C(S1)C2=CSC3=CC=CC=C32 AAWJSDFZSZAIBG-UHFFFAOYSA-N 0.000 description 3
- WGSNGUSPSPXBEB-UHFFFAOYSA-N COC(=O)CCC(=O)C1=CC(=C(S1)Br)Br Chemical compound COC(=O)CCC(=O)C1=CC(=C(S1)Br)Br WGSNGUSPSPXBEB-UHFFFAOYSA-N 0.000 description 3
- YSOTWHVOECBYHI-UHFFFAOYSA-N COC(=O)CCC(=O)C1=CC(=CO1)C2=COC3=CC=CC=C32 Chemical compound COC(=O)CCC(=O)C1=CC(=CO1)C2=COC3=CC=CC=C32 YSOTWHVOECBYHI-UHFFFAOYSA-N 0.000 description 3
- PFECNMRJJJTKIG-UHFFFAOYSA-N COC(=O)CCC(=O)C1=CC(=CS1)C2=CNC3=CC=CC=C32 Chemical compound COC(=O)CCC(=O)C1=CC(=CS1)C2=CNC3=CC=CC=C32 PFECNMRJJJTKIG-UHFFFAOYSA-N 0.000 description 3
- GFGMUYDLRJLITA-UHFFFAOYSA-N COC1=C(C=C(C=C1)C2=COC(=C2)C(=O)CC(=O)OC)OC Chemical compound COC1=C(C=C(C=C1)C2=COC(=C2)C(=O)CC(=O)OC)OC GFGMUYDLRJLITA-UHFFFAOYSA-N 0.000 description 3
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 3
- 102100031256 Cyclic GMP-AMP synthase Human genes 0.000 description 3
- 101710118064 Cyclic GMP-AMP synthase Proteins 0.000 description 3
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 description 3
- 206010014967 Ependymoma Diseases 0.000 description 3
- 101001117312 Homo sapiens Programmed cell death 1 ligand 2 Proteins 0.000 description 3
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 3
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 description 3
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 3
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 3
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 3
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 3
- 102000012064 NLR Proteins Human genes 0.000 description 3
- 108091005686 NOD-like receptors Proteins 0.000 description 3
- 201000010133 Oligodendroglioma Diseases 0.000 description 3
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 3
- 102000002689 Toll-like receptor Human genes 0.000 description 3
- 108020000411 Toll-like receptor Proteins 0.000 description 3
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 3
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- ZEEBGORNQSEQBE-UHFFFAOYSA-N [2-(3-phenylphenoxy)-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound C1(=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)C1=CC=CC=C1 ZEEBGORNQSEQBE-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000033289 adaptive immune response Effects 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 210000000013 bile duct Anatomy 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 229940125758 compound 15 Drugs 0.000 description 3
- 239000002254 cytotoxic agent Substances 0.000 description 3
- 231100000599 cytotoxic agent Toxicity 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 229960000975 daunorubicin Drugs 0.000 description 3
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 3
- 229960003603 decitabine Drugs 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- UZVGSSNIUNSOFA-UHFFFAOYSA-N dibenzofuran-1-carboxylic acid Chemical compound O1C2=CC=CC=C2C2=C1C=CC=C2C(=O)O UZVGSSNIUNSOFA-UHFFFAOYSA-N 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 3
- 229960005420 etoposide Drugs 0.000 description 3
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- HYBBIBNJHNGZAN-UHFFFAOYSA-N furfural Chemical compound O=CC1=CC=CO1 HYBBIBNJHNGZAN-UHFFFAOYSA-N 0.000 description 3
- 125000002541 furyl group Chemical group 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 208000003884 gestational trophoblastic disease Diseases 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 239000002955 immunomodulating agent Substances 0.000 description 3
- 229940121354 immunomodulator Drugs 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 230000002601 intratumoral effect Effects 0.000 description 3
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 3
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 230000001613 neoplastic effect Effects 0.000 description 3
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Chemical group COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 125000000168 pyrrolyl group Chemical group 0.000 description 3
- 108091006082 receptor inhibitors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 229930002330 retinoic acid Natural products 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 201000010153 skin papilloma Diseases 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 125000000335 thiazolyl group Chemical group 0.000 description 3
- 206010044412 transitional cell carcinoma Diseases 0.000 description 3
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- OQALQEZJNNWAFM-UHFFFAOYSA-N 1-(4,5-dibromothiophen-2-yl)ethanone Chemical compound CC(=O)C1=CC(Br)=C(Br)S1 OQALQEZJNNWAFM-UHFFFAOYSA-N 0.000 description 2
- INRXEWBAPFKMKA-UHFFFAOYSA-N 1-bromo-2-(2,2-diethoxyethoxy)benzene Chemical compound CCOC(OCC)COC1=CC=CC=C1Br INRXEWBAPFKMKA-UHFFFAOYSA-N 0.000 description 2
- BXNLYIJBCFCSBQ-UHFFFAOYSA-N 1-bromo-3-(2,2-diethoxyethoxy)benzene Chemical compound CCOC(OCC)COC1=CC=CC(Br)=C1 BXNLYIJBCFCSBQ-UHFFFAOYSA-N 0.000 description 2
- ATRJNSFQBYKFSM-UHFFFAOYSA-N 2,3-dibromothiophene Chemical compound BrC=1C=CSC=1Br ATRJNSFQBYKFSM-UHFFFAOYSA-N 0.000 description 2
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 2
- SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 description 2
- IFVFKSWGVOIEIM-UHFFFAOYSA-N 3-bromo-5-fluoro-1-benzofuran Chemical compound FC1=CC=C2OC=C(Br)C2=C1 IFVFKSWGVOIEIM-UHFFFAOYSA-N 0.000 description 2
- XVYVGSOEQYQNNJ-UHFFFAOYSA-N 3-bromo-7-fluoro-1-benzofuran Chemical compound FC1=CC=CC2=C1OC=C2Br XVYVGSOEQYQNNJ-UHFFFAOYSA-N 0.000 description 2
- KSJRECIUOPOGCZ-UHFFFAOYSA-N 3-bromofuro[2,3-c]pyridine Chemical compound N1=CC=C2C(Br)=COC2=C1 KSJRECIUOPOGCZ-UHFFFAOYSA-N 0.000 description 2
- XCMISAPCWHTVNG-UHFFFAOYSA-N 3-bromothiophene Chemical compound BrC=1C=CSC=1 XCMISAPCWHTVNG-UHFFFAOYSA-N 0.000 description 2
- CTRJZPMXUDWQRJ-UHFFFAOYSA-N 3-fluoro-2-(trimethylsilylmethoxy)benzaldehyde Chemical compound C[Si](C)(C)COC1=C(F)C=CC=C1C=O CTRJZPMXUDWQRJ-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 2
- WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 2
- YFKGZOJEQUDHAD-UHFFFAOYSA-N 4-bromo-1-benzofuran Chemical compound BrC1=CC=CC2=C1C=CO2 YFKGZOJEQUDHAD-UHFFFAOYSA-N 0.000 description 2
- PWKPAIVHIHDYNR-UHFFFAOYSA-N 4-bromothieno[2,3-b]pyridine Chemical compound BrC1=CC=NC2=C1C=CS2 PWKPAIVHIHDYNR-UHFFFAOYSA-N 0.000 description 2
- LPQDKBVSCMLJMK-UHFFFAOYSA-N 4-bromothieno[2,3-c]pyridine Chemical compound BrC1=CN=CC2=C1C=CS2 LPQDKBVSCMLJMK-UHFFFAOYSA-N 0.000 description 2
- BBXQYOQXGGJUFK-UHFFFAOYSA-N 6-bromo-1-benzofuran Chemical compound BrC1=CC=C2C=COC2=C1 BBXQYOQXGGJUFK-UHFFFAOYSA-N 0.000 description 2
- GPZPQJITKRSVQJ-UHFFFAOYSA-N 7-bromo-1-benzofuran Chemical compound BrC1=CC=CC2=C1OC=C2 GPZPQJITKRSVQJ-UHFFFAOYSA-N 0.000 description 2
- WPCSQSMSSNPKKB-UHFFFAOYSA-N 7-fluoro-1-benzofuran Chemical compound FC1=CC=CC2=C1OC=C2 WPCSQSMSSNPKKB-UHFFFAOYSA-N 0.000 description 2
- YIHJHVSDENEPEU-UHFFFAOYSA-N 7-fluoro-2,3-dihydro-1-benzofuran-3-ol Chemical compound C1=CC=C(F)C2=C1C(O)CO2 YIHJHVSDENEPEU-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 2
- RGFNKJPZSAJYLJ-UHFFFAOYSA-N C1=C(OC=C1Br)C(=O)CCC#N Chemical compound C1=C(OC=C1Br)C(=O)CCC#N RGFNKJPZSAJYLJ-UHFFFAOYSA-N 0.000 description 2
- XUCRZIVMLOVMAC-UHFFFAOYSA-N C1=CC(=C2C=COC2=C1)C3=COC(=C3)C(=O)CCC(=O)O Chemical compound C1=CC(=C2C=COC2=C1)C3=COC(=C3)C(=O)CCC(=O)O XUCRZIVMLOVMAC-UHFFFAOYSA-N 0.000 description 2
- NKDJZWOKILWNPN-UHFFFAOYSA-N C1=CC(=CC2=C1C=CO2)C3=COC(=C3)C(=O)CCC(=O)O Chemical compound C1=CC(=CC2=C1C=CO2)C3=COC(=C3)C(=O)CCC(=O)O NKDJZWOKILWNPN-UHFFFAOYSA-N 0.000 description 2
- CUSWBSSJXWUHNP-UHFFFAOYSA-N C1=CC2=C(C(=C1)C3=CSC(=C3)C(=O)CCC(=O)O)OC=C2 Chemical compound C1=CC2=C(C(=C1)C3=CSC(=C3)C(=O)CCC(=O)O)OC=C2 CUSWBSSJXWUHNP-UHFFFAOYSA-N 0.000 description 2
- LHBFBXUQZDCEFB-UHFFFAOYSA-N C1=CC2=C(C(=C1)F)C(=CN2)C3=COC(=C3)C(=O)CCC(=O)O Chemical compound C1=CC2=C(C(=C1)F)C(=CN2)C3=COC(=C3)C(=O)CCC(=O)O LHBFBXUQZDCEFB-UHFFFAOYSA-N 0.000 description 2
- JOOBXOCQPHAKQZ-UHFFFAOYSA-N C1=CC2=C(C(=C1)F)C(=CN2)C3=CSC(=C3)C(=O)CCC(=O)O Chemical compound C1=CC2=C(C(=C1)F)C(=CN2)C3=CSC(=C3)C(=O)CCC(=O)O JOOBXOCQPHAKQZ-UHFFFAOYSA-N 0.000 description 2
- JLLKXSQDQLEFQK-UHFFFAOYSA-N C1=CC2=C(C(=C1)F)NC=C2C3=COC(=C3)C(=O)CCC(=O)O Chemical compound C1=CC2=C(C(=C1)F)NC=C2C3=COC(=C3)C(=O)CCC(=O)O JLLKXSQDQLEFQK-UHFFFAOYSA-N 0.000 description 2
- RRFCNGVALXBCPS-UHFFFAOYSA-N C1=CC2=C(C(=C1)F)NC=C2C3=CSC(=C3)C(=O)CCC(=O)O Chemical compound C1=CC2=C(C(=C1)F)NC=C2C3=CSC(=C3)C(=O)CCC(=O)O RRFCNGVALXBCPS-UHFFFAOYSA-N 0.000 description 2
- YFQWQRYYWABIKL-UHFFFAOYSA-N C1=CC2=C(C(=C1)F)OC=C2C3=CSC(=C3)C(=O)CCC(=O)O Chemical compound C1=CC2=C(C(=C1)F)OC=C2C3=CSC(=C3)C(=O)CCC(=O)O YFQWQRYYWABIKL-UHFFFAOYSA-N 0.000 description 2
- TYMSYVADYIVGBD-UHFFFAOYSA-N C1=CC2=C(C=C1C#N)C(=CN2)C3=COC(=C3)C(=O)CCC(=O)O Chemical compound C1=CC2=C(C=C1C#N)C(=CN2)C3=COC(=C3)C(=O)CCC(=O)O TYMSYVADYIVGBD-UHFFFAOYSA-N 0.000 description 2
- BGAIHIHTYJOOLC-UHFFFAOYSA-N C1=CC2=C(C=C1C(F)(F)F)NC=C2C3=CSC(=C3)C(=O)CCC(=O)O Chemical compound C1=CC2=C(C=C1C(F)(F)F)NC=C2C3=CSC(=C3)C(=O)CCC(=O)O BGAIHIHTYJOOLC-UHFFFAOYSA-N 0.000 description 2
- LFRDCAIGOXJOBG-UHFFFAOYSA-N C1=CC2=C(C=C1Cl)NC=C2C3=CSC(=C3)C(=O)CCC(=O)O Chemical compound C1=CC2=C(C=C1Cl)NC=C2C3=CSC(=C3)C(=O)CCC(=O)O LFRDCAIGOXJOBG-UHFFFAOYSA-N 0.000 description 2
- KNDYCZJTNSOKFT-UHFFFAOYSA-N C1=CC2=C(C=C1F)C(=CN2)C3=COC(=C3)C(=O)CCC(=O)O Chemical compound C1=CC2=C(C=C1F)C(=CN2)C3=COC(=C3)C(=O)CCC(=O)O KNDYCZJTNSOKFT-UHFFFAOYSA-N 0.000 description 2
- JSZCJFILHYDYLG-UHFFFAOYSA-N C1=CC2=C(C=C1F)C(=CN2)C3=CSC(=C3)C(=O)CCC(=O)O Chemical compound C1=CC2=C(C=C1F)C(=CN2)C3=CSC(=C3)C(=O)CCC(=O)O JSZCJFILHYDYLG-UHFFFAOYSA-N 0.000 description 2
- ILYVNEJFOUQWOT-UHFFFAOYSA-N C1=CC2=C(C=C1F)C(=CO2)C3=CSC(=C3)C(=O)CCC(=O)O Chemical compound C1=CC2=C(C=C1F)C(=CO2)C3=CSC(=C3)C(=O)CCC(=O)O ILYVNEJFOUQWOT-UHFFFAOYSA-N 0.000 description 2
- ZXXKFZGJOPQMPZ-UHFFFAOYSA-N C1=CC2=C(C=C1F)NC=C2C3=COC(=C3)C(=O)CCC(=O)O Chemical compound C1=CC2=C(C=C1F)NC=C2C3=COC(=C3)C(=O)CCC(=O)O ZXXKFZGJOPQMPZ-UHFFFAOYSA-N 0.000 description 2
- LIOANHVMMNEYMJ-UHFFFAOYSA-N C1=CC2=C(C=C1F)NC=C2C3=CSC(=C3)C(=O)CCC(=O)O Chemical compound C1=CC2=C(C=C1F)NC=C2C3=CSC(=C3)C(=O)CCC(=O)O LIOANHVMMNEYMJ-UHFFFAOYSA-N 0.000 description 2
- PTTUWEZWJZCZGY-UHFFFAOYSA-N C1=CC2=C(C=C1F)OC=C2C3=CSC(=C3)C(=O)CCC(=O)O Chemical compound C1=CC2=C(C=C1F)OC=C2C3=CSC(=C3)C(=O)CCC(=O)O PTTUWEZWJZCZGY-UHFFFAOYSA-N 0.000 description 2
- YDWZEDMNGHCEKZ-UHFFFAOYSA-N C1=CC2=C(C=CO2)C=C1C3=COC(=C3)C(=O)CCC(=O)O Chemical compound C1=CC2=C(C=CO2)C=C1C3=COC(=C3)C(=O)CCC(=O)O YDWZEDMNGHCEKZ-UHFFFAOYSA-N 0.000 description 2
- LAECSUBVOKQMII-UHFFFAOYSA-N C1=CC=C(C=C1)C2=CSC(=C2)C(=O)CCC(=O)O Chemical compound C1=CC=C(C=C1)C2=CSC(=C2)C(=O)CCC(=O)O LAECSUBVOKQMII-UHFFFAOYSA-N 0.000 description 2
- DONFCXWBKDTUQY-UHFFFAOYSA-N C1=CC=C2C(=C1)C(=CN2)C3=CC(=CS3)C(=O)CCC(=O)O Chemical compound C1=CC=C2C(=C1)C(=CN2)C3=CC(=CS3)C(=O)CCC(=O)O DONFCXWBKDTUQY-UHFFFAOYSA-N 0.000 description 2
- WOQJAXAQUCNDIM-UHFFFAOYSA-N C1=CC=C2C(=C1)C(=CN2)C3=CSC(=C3)C(=O)C(C(=O)O)(F)F Chemical compound C1=CC=C2C(=C1)C(=CN2)C3=CSC(=C3)C(=O)C(C(=O)O)(F)F WOQJAXAQUCNDIM-UHFFFAOYSA-N 0.000 description 2
- ARQYACQJQVLTQI-UHFFFAOYSA-N C1=CC=C2C(=C1)C(=CN2)C3=CSC(=C3F)C(=O)CCC(=O)O Chemical compound C1=CC=C2C(=C1)C(=CN2)C3=CSC(=C3F)C(=O)CCC(=O)O ARQYACQJQVLTQI-UHFFFAOYSA-N 0.000 description 2
- XTURCBNYFBZZMG-UHFFFAOYSA-N C1=CC=C2C(=C1)C(=CN2)C3=CSC(=N3)C(=O)CCC(=O)O Chemical compound C1=CC=C2C(=C1)C(=CN2)C3=CSC(=N3)C(=O)CCC(=O)O XTURCBNYFBZZMG-UHFFFAOYSA-N 0.000 description 2
- UEZCQXINDDWXPS-UHFFFAOYSA-N C1=CC=C2C(=C1)C(=CO2)C3=CNC(=C3)C(=O)CCC(=O)O Chemical compound C1=CC=C2C(=C1)C(=CO2)C3=CNC(=C3)C(=O)CCC(=O)O UEZCQXINDDWXPS-UHFFFAOYSA-N 0.000 description 2
- KEUYRDOEBFXQMY-UHFFFAOYSA-N C1=CC=C2C(=C1)C(=CO2)C3=COC(=C3)C(=O)CCC(=O)N Chemical compound C1=CC=C2C(=C1)C(=CO2)C3=COC(=C3)C(=O)CCC(=O)N KEUYRDOEBFXQMY-UHFFFAOYSA-N 0.000 description 2
- MBIJFKLXNBHMNP-UHFFFAOYSA-N C1=CC=C2C(=C1)C(=CO2)C3=COC(=C3)C(=O)CCC(=O)O Chemical compound C1=CC=C2C(=C1)C(=CO2)C3=COC(=C3)C(=O)CCC(=O)O MBIJFKLXNBHMNP-UHFFFAOYSA-N 0.000 description 2
- FUHHAZKAXYPIMP-UHFFFAOYSA-N C1=CC=C2C(=C1)C(=CO2)C3=CSC(=C3)C(=O)CCC(=O)O Chemical compound C1=CC=C2C(=C1)C(=CO2)C3=CSC(=C3)C(=O)CCC(=O)O FUHHAZKAXYPIMP-UHFFFAOYSA-N 0.000 description 2
- YSRZUFPDCZEOLY-UHFFFAOYSA-N C1=CC=C2C(=C1)C(=CO2)C3=CSC(=N3)C(=O)CCC(=O)O Chemical compound C1=CC=C2C(=C1)C(=CO2)C3=CSC(=N3)C(=O)CCC(=O)O YSRZUFPDCZEOLY-UHFFFAOYSA-N 0.000 description 2
- RFBSFLSGEVTBAL-UHFFFAOYSA-N C1=CC=C2C(=C1)C(OC2=O)OC(=O)CCC(=O)C3=CC(=CO3)C4=CNC5=CC=CC=C54 Chemical compound C1=CC=C2C(=C1)C(OC2=O)OC(=O)CCC(=O)C3=CC(=CO3)C4=CNC5=CC=CC=C54 RFBSFLSGEVTBAL-UHFFFAOYSA-N 0.000 description 2
- NQNGCRGCKPCIKE-UHFFFAOYSA-N C1=CC=C2C(=C1)C=C(O2)C3=COC(=C3)C(=O)CCC(=O)O Chemical compound C1=CC=C2C(=C1)C=C(O2)C3=COC(=C3)C(=O)CCC(=O)O NQNGCRGCKPCIKE-UHFFFAOYSA-N 0.000 description 2
- IQPRCDYCPXWCSC-UHFFFAOYSA-N C1=CC=C2C(=C1)C=CC=C2C3=CSC(=C3)C(=O)CCC(=O)O Chemical compound C1=CC=C2C(=C1)C=CC=C2C3=CSC(=C3)C(=O)CCC(=O)O IQPRCDYCPXWCSC-UHFFFAOYSA-N 0.000 description 2
- ZOUQFONZVVTJRU-UHFFFAOYSA-N C1=CSC2=C1C(=CN=C2)C3=CSC(=C3)C(=O)CCC(=O)O Chemical compound C1=CSC2=C1C(=CN=C2)C3=CSC(=C3)C(=O)CCC(=O)O ZOUQFONZVVTJRU-UHFFFAOYSA-N 0.000 description 2
- WMOBCOJWXRZIJX-UHFFFAOYSA-N C1=CSC2=C1OC=C2C3=COC(=C3)C(=O)CCC(=O)O Chemical compound C1=CSC2=C1OC=C2C3=COC(=C3)C(=O)CCC(=O)O WMOBCOJWXRZIJX-UHFFFAOYSA-N 0.000 description 2
- DTHVUJBIYHWVLQ-UHFFFAOYSA-N CC(C)(C)OC(=O)CC(=O)C1=C(C(=CS1)Br)F Chemical compound CC(C)(C)OC(=O)CC(=O)C1=C(C(=CS1)Br)F DTHVUJBIYHWVLQ-UHFFFAOYSA-N 0.000 description 2
- JXNRAIHNRTXQGM-UHFFFAOYSA-N CC(C)(C)OC(=O)N1C=C(C2=C1C(=CC=C2)F)Br Chemical compound CC(C)(C)OC(=O)N1C=C(C2=C1C(=CC=C2)F)Br JXNRAIHNRTXQGM-UHFFFAOYSA-N 0.000 description 2
- YQLXYAKYGQLYQO-UHFFFAOYSA-N CC(C)(C)OC(=O)N1C=C(C2=C1C(=CC=C2)F)C3=COC(=C3)C(=O)CCC(=O)OC Chemical compound CC(C)(C)OC(=O)N1C=C(C2=C1C(=CC=C2)F)C3=COC(=C3)C(=O)CCC(=O)OC YQLXYAKYGQLYQO-UHFFFAOYSA-N 0.000 description 2
- IFESZRISGYAGHX-UHFFFAOYSA-N CC(C)(C)OC(=O)N1C=C(C2=C1C(=CC=C2)F)C3=CSC(=C3)C(=O)CCC(=O)OC Chemical compound CC(C)(C)OC(=O)N1C=C(C2=C1C(=CC=C2)F)C3=CSC(=C3)C(=O)CCC(=O)OC IFESZRISGYAGHX-UHFFFAOYSA-N 0.000 description 2
- BLPDPEKXESODAS-UHFFFAOYSA-N CC(C)(C)OC(=O)N1C=C(C2=C1C(=CC=C2)F)C3=CSC(=C3)C=O Chemical compound CC(C)(C)OC(=O)N1C=C(C2=C1C(=CC=C2)F)C3=CSC(=C3)C=O BLPDPEKXESODAS-UHFFFAOYSA-N 0.000 description 2
- VUONIJHJWWRIRO-UHFFFAOYSA-N CC(C)(C)OC(=O)N1C=C(C2=C1C=C(C=C2)C(F)(F)F)C3=CSC(=C3)C(=O)CCC(=O)OC Chemical compound CC(C)(C)OC(=O)N1C=C(C2=C1C=C(C=C2)C(F)(F)F)C3=CSC(=C3)C(=O)CCC(=O)OC VUONIJHJWWRIRO-UHFFFAOYSA-N 0.000 description 2
- NLRRTVYEPXXAAT-UHFFFAOYSA-N CC(C)(C)OC(=O)N1C=C(C2=C1C=C(C=C2)Cl)C3=CSC(=C3)C(=O)CCC(=O)OC Chemical compound CC(C)(C)OC(=O)N1C=C(C2=C1C=C(C=C2)Cl)C3=CSC(=C3)C(=O)CCC(=O)OC NLRRTVYEPXXAAT-UHFFFAOYSA-N 0.000 description 2
- AMFBMMQUAVCTRJ-UHFFFAOYSA-N CC(C)(C)OC(=O)N1C=C(C2=C1C=C(C=C2)F)C3=CSC(=C3)C(=O)CCC(=O)OC Chemical compound CC(C)(C)OC(=O)N1C=C(C2=C1C=C(C=C2)F)C3=CSC(=C3)C(=O)CCC(=O)OC AMFBMMQUAVCTRJ-UHFFFAOYSA-N 0.000 description 2
- XHEBCJCJQBPHIX-UHFFFAOYSA-N CC(C)(C)OC(=O)N1C=C(C2=C1C=CC(=C2)C#N)C3=COC(=C3)C(=O)CCC(=O)OC Chemical compound CC(C)(C)OC(=O)N1C=C(C2=C1C=CC(=C2)C#N)C3=COC(=C3)C(=O)CCC(=O)OC XHEBCJCJQBPHIX-UHFFFAOYSA-N 0.000 description 2
- BNGNWJZTDSDULQ-UHFFFAOYSA-N CC(C)(C)OC(=O)N1C=C(C2=C1C=CC(=C2)F)C3=COC(=C3)C(=O)CCC(=O)OC Chemical compound CC(C)(C)OC(=O)N1C=C(C2=C1C=CC(=C2)F)C3=COC(=C3)C(=O)CCC(=O)OC BNGNWJZTDSDULQ-UHFFFAOYSA-N 0.000 description 2
- HJURTWVGPIASNS-UHFFFAOYSA-N CC(C)(C)OC(=O)N1C=C(C2=C1C=CC(=C2)F)C3=CSC(=C3)C(=O)CCC(=O)OC Chemical compound CC(C)(C)OC(=O)N1C=C(C2=C1C=CC(=C2)F)C3=CSC(=C3)C(=O)CCC(=O)OC HJURTWVGPIASNS-UHFFFAOYSA-N 0.000 description 2
- RXNVCTURYAXCHO-UHFFFAOYSA-N CC(C)(C)OC(=O)N1C=C(C2=C1C=CC=C2F)Br Chemical compound CC(C)(C)OC(=O)N1C=C(C2=C1C=CC=C2F)Br RXNVCTURYAXCHO-UHFFFAOYSA-N 0.000 description 2
- VBRCJXBBKROLHF-UHFFFAOYSA-N CC(C)(C)OC(=O)N1C=C(C2=C1C=CC=C2F)C3=COC(=C3)C(=O)CCC(=O)OC Chemical compound CC(C)(C)OC(=O)N1C=C(C2=C1C=CC=C2F)C3=COC(=C3)C(=O)CCC(=O)OC VBRCJXBBKROLHF-UHFFFAOYSA-N 0.000 description 2
- DJEKCSYEPQNKDM-UHFFFAOYSA-N CC(C)(C)OC(=O)N1C=C(C2=C1C=CC=C2F)C3=CSC(=C3)C(=O)CCC(=O)OC Chemical compound CC(C)(C)OC(=O)N1C=C(C2=C1C=CC=C2F)C3=CSC(=C3)C(=O)CCC(=O)OC DJEKCSYEPQNKDM-UHFFFAOYSA-N 0.000 description 2
- HHHGIIJYRQFNKV-UHFFFAOYSA-N CC(C)(C)OC(=O)N1C=C(C2=CC=CC=C21)C3=CC(=CS3)C=O Chemical compound CC(C)(C)OC(=O)N1C=C(C2=CC=CC=C21)C3=CC(=CS3)C=O HHHGIIJYRQFNKV-UHFFFAOYSA-N 0.000 description 2
- IZYGTHOGDIJZQA-UHFFFAOYSA-N CC(C)(C)OC(=O)N1C=C(C2=CC=CC=C21)C3=CSC(=C3)C(=O)CC(=O)OC Chemical compound CC(C)(C)OC(=O)N1C=C(C2=CC=CC=C21)C3=CSC(=C3)C(=O)CC(=O)OC IZYGTHOGDIJZQA-UHFFFAOYSA-N 0.000 description 2
- STISUWQIDSAOSF-UHFFFAOYSA-N CC(C)(C)OC(=O)N1C=C(C2=CC=CC=C21)C3=CSC(=C3)C=O Chemical compound CC(C)(C)OC(=O)N1C=C(C2=CC=CC=C21)C3=CSC(=C3)C=O STISUWQIDSAOSF-UHFFFAOYSA-N 0.000 description 2
- FPDPAHAEIFAEHU-UHFFFAOYSA-N CC(C)(C)OC(=O)N1C=C(C2=CC=CC=C21)C3=CSC(=C3F)C(=O)CCC(=O)OC Chemical compound CC(C)(C)OC(=O)N1C=C(C2=CC=CC=C21)C3=CSC(=C3F)C(=O)CCC(=O)OC FPDPAHAEIFAEHU-UHFFFAOYSA-N 0.000 description 2
- DBRTXQXHKQJBJB-UHFFFAOYSA-N CC(CC(=O)C1=CC(=CO1)C2=COC3=CC=CC=C32)C(=O)O Chemical compound CC(CC(=O)C1=CC(=CO1)C2=COC3=CC=CC=C32)C(=O)O DBRTXQXHKQJBJB-UHFFFAOYSA-N 0.000 description 2
- TYBLMNRPALHFDB-UHFFFAOYSA-N CC1=C(C=C(S1)C(=O)CCC(=O)OC)Br Chemical compound CC1=C(C=C(S1)C(=O)CCC(=O)OC)Br TYBLMNRPALHFDB-UHFFFAOYSA-N 0.000 description 2
- DKHROTBGHOQEJT-UHFFFAOYSA-N CC1=CC2=C(C=C1)C(=CN2)C3=COC(=C3)C(=O)CCC(=O)O Chemical compound CC1=CC2=C(C=C1)C(=CN2)C3=COC(=C3)C(=O)CCC(=O)O DKHROTBGHOQEJT-UHFFFAOYSA-N 0.000 description 2
- DLUOLJYCNTUMKD-UHFFFAOYSA-M CC1SC=C(CCO)N1CC1=CC=CC=C1.[Li+].[Cl-] Chemical compound CC1SC=C(CCO)N1CC1=CC=CC=C1.[Li+].[Cl-] DLUOLJYCNTUMKD-UHFFFAOYSA-M 0.000 description 2
- XULFXIYOHASFBM-UHFFFAOYSA-N CCCCOC(=O)C(C)CC(=O)C1=CC(=CO1)C2=COC3=CC=CC=C32 Chemical compound CCCCOC(=O)C(C)CC(=O)C1=CC(=CO1)C2=COC3=CC=CC=C32 XULFXIYOHASFBM-UHFFFAOYSA-N 0.000 description 2
- OXLSBNLSAXMKNW-UHFFFAOYSA-N CCOC(=O)C(C(=O)C1=CC(=CS1)C2=CN(C3=C2C=CC=C3F)C(=O)OC(C)(C)C)(F)F Chemical compound CCOC(=O)C(C(=O)C1=CC(=CS1)C2=CN(C3=C2C=CC=C3F)C(=O)OC(C)(C)C)(F)F OXLSBNLSAXMKNW-UHFFFAOYSA-N 0.000 description 2
- JPQJDMZUBSUUDE-UHFFFAOYSA-N CCOC(=O)C(C(C1=CC(=CS1)C2=CN(C3=C2C=CC=C3F)C(=O)OC(C)(C)C)O)(F)F Chemical compound CCOC(=O)C(C(C1=CC(=CS1)C2=CN(C3=C2C=CC=C3F)C(=O)OC(C)(C)C)O)(F)F JPQJDMZUBSUUDE-UHFFFAOYSA-N 0.000 description 2
- PVYQCWHURQSNII-UHFFFAOYSA-N COC(=O)C1(CC1)C(=O)c1cc(Br)cs1 Chemical compound COC(=O)C1(CC1)C(=O)c1cc(Br)cs1 PVYQCWHURQSNII-UHFFFAOYSA-N 0.000 description 2
- WUOOMIFONAGQMX-UHFFFAOYSA-N COC(=O)CC(=O)C1=CC(=C(S1)Br)Br Chemical compound COC(=O)CC(=O)C1=CC(=C(S1)Br)Br WUOOMIFONAGQMX-UHFFFAOYSA-N 0.000 description 2
- OACBDGWNLCHHRR-UHFFFAOYSA-N COC(=O)CC(=O)C1=CC(=CO1)Br Chemical compound COC(=O)CC(=O)C1=CC(=CO1)Br OACBDGWNLCHHRR-UHFFFAOYSA-N 0.000 description 2
- HFIRTYAJIFWHCB-UHFFFAOYSA-N COC(=O)CCC(=O)C1=C(C(=CS1)Br)F Chemical compound COC(=O)CCC(=O)C1=C(C(=CS1)Br)F HFIRTYAJIFWHCB-UHFFFAOYSA-N 0.000 description 2
- NVMDHSQUAGOTOU-UHFFFAOYSA-N COC(=O)CCC(=O)C1=C(C(=CS1)C2=CNC3=CC=CC=C32)F Chemical compound COC(=O)CCC(=O)C1=C(C(=CS1)C2=CNC3=CC=CC=C32)F NVMDHSQUAGOTOU-UHFFFAOYSA-N 0.000 description 2
- SPAOTOWURMXTTH-UHFFFAOYSA-N COC(=O)CCC(=O)C1=C(C=CS1)Cl Chemical compound COC(=O)CCC(=O)C1=C(C=CS1)Cl SPAOTOWURMXTTH-UHFFFAOYSA-N 0.000 description 2
- LDBSKZKPGIJABE-UHFFFAOYSA-N COC(=O)CCC(=O)C1=CC(=CN1)Br Chemical compound COC(=O)CCC(=O)C1=CC(=CN1)Br LDBSKZKPGIJABE-UHFFFAOYSA-N 0.000 description 2
- WJGPGQJYWSZVNL-UHFFFAOYSA-N COC(=O)CCC(=O)C1=CC(=CN1)C2=COC3=CC=CC=C32 Chemical compound COC(=O)CCC(=O)C1=CC(=CN1)C2=COC3=CC=CC=C32 WJGPGQJYWSZVNL-UHFFFAOYSA-N 0.000 description 2
- IMISBFKHWVCWCZ-UHFFFAOYSA-N COC(=O)CCC(=O)C1=CC(=CO1)C2=C3C=COC3=CC=C2 Chemical compound COC(=O)CCC(=O)C1=CC(=CO1)C2=C3C=COC3=CC=C2 IMISBFKHWVCWCZ-UHFFFAOYSA-N 0.000 description 2
- HXTDDEHXFDAIBK-UHFFFAOYSA-N COC(=O)CCC(=O)C1=CC(=CO1)C2=CC3=C(C=C2)C=CO3 Chemical compound COC(=O)CCC(=O)C1=CC(=CO1)C2=CC3=C(C=C2)C=CO3 HXTDDEHXFDAIBK-UHFFFAOYSA-N 0.000 description 2
- HTJKVLKFTNDRLC-UHFFFAOYSA-N COC(=O)CCC(=O)C1=CC(=CO1)C2=CC3=C(C=C2)OC=C3 Chemical compound COC(=O)CCC(=O)C1=CC(=CO1)C2=CC3=C(C=C2)OC=C3 HTJKVLKFTNDRLC-UHFFFAOYSA-N 0.000 description 2
- FRHHYCRKJQYOEY-UHFFFAOYSA-N COC(=O)CCC(=O)C1=CC(=CO1)C2=CC3=CC=CC=C3O2 Chemical compound COC(=O)CCC(=O)C1=CC(=CO1)C2=CC3=CC=CC=C3O2 FRHHYCRKJQYOEY-UHFFFAOYSA-N 0.000 description 2
- VIUVUQJMSYHDJX-UHFFFAOYSA-N COC(=O)CCC(=O)C1=CC(=CO1)C2=COC3=C2C=CC(=C3)F Chemical compound COC(=O)CCC(=O)C1=CC(=CO1)C2=COC3=C2C=CC(=C3)F VIUVUQJMSYHDJX-UHFFFAOYSA-N 0.000 description 2
- LFENWAMQXJCTRJ-UHFFFAOYSA-N COC(=O)CCC(=O)C1=CC(=CS1)C2=CC=CC3=C2OC=C3 Chemical compound COC(=O)CCC(=O)C1=CC(=CS1)C2=CC=CC3=C2OC=C3 LFENWAMQXJCTRJ-UHFFFAOYSA-N 0.000 description 2
- UTKZGYFEDRBVII-UHFFFAOYSA-N COC(=O)CCC(=O)C1=CC(=CS1)C2=CC=CC3=CC=CC=C32 Chemical compound COC(=O)CCC(=O)C1=CC(=CS1)C2=CC=CC3=CC=CC=C32 UTKZGYFEDRBVII-UHFFFAOYSA-N 0.000 description 2
- GZTSFKZEYVLNQZ-UHFFFAOYSA-N COC(=O)CCC(=O)C1=CC(=CS1)C2=CC=CC=C2 Chemical compound COC(=O)CCC(=O)C1=CC(=CS1)C2=CC=CC=C2 GZTSFKZEYVLNQZ-UHFFFAOYSA-N 0.000 description 2
- SKTBILQUQXYRTC-UHFFFAOYSA-N COC(=O)CCC(=O)C1=CC(=CS1)C2=COC3=C2C=C(C=C3)F Chemical compound COC(=O)CCC(=O)C1=CC(=CS1)C2=COC3=C2C=C(C=C3)F SKTBILQUQXYRTC-UHFFFAOYSA-N 0.000 description 2
- XCMVRVUGLLRMNJ-UHFFFAOYSA-N COC(=O)CCC(=O)C1=CC(=CS1)C2=COC3=C2C=CC(=C3)F Chemical compound COC(=O)CCC(=O)C1=CC(=CS1)C2=COC3=C2C=CC(=C3)F XCMVRVUGLLRMNJ-UHFFFAOYSA-N 0.000 description 2
- NGNVUGALENVIFW-UHFFFAOYSA-N COC(=O)CCC(=O)C1=CC(=CS1)C2=COC3=C2C=CC=C3F Chemical compound COC(=O)CCC(=O)C1=CC(=CS1)C2=COC3=C2C=CC=C3F NGNVUGALENVIFW-UHFFFAOYSA-N 0.000 description 2
- GOVBATPCCJRSRJ-UHFFFAOYSA-N COC(=O)CCC(=O)C1=CC(=CS1)C2=COC3=CC=CC=C32 Chemical compound COC(=O)CCC(=O)C1=CC(=CS1)C2=COC3=CC=CC=C32 GOVBATPCCJRSRJ-UHFFFAOYSA-N 0.000 description 2
- MUVHWNRXYBGYID-UHFFFAOYSA-N COC(=O)CCC(=O)C1=NC(=CS1)Br Chemical compound COC(=O)CCC(=O)C1=NC(=CS1)Br MUVHWNRXYBGYID-UHFFFAOYSA-N 0.000 description 2
- NAGDQZGPJREAGF-UHFFFAOYSA-N COC(=O)CCC(=O)C1=NC(=CS1)C2=CNC3=CC=CC=C32 Chemical compound COC(=O)CCC(=O)C1=NC(=CS1)C2=CNC3=CC=CC=C32 NAGDQZGPJREAGF-UHFFFAOYSA-N 0.000 description 2
- POIABEUHJMTGMB-UHFFFAOYSA-N COC(=O)CCC(=O)C1=NC(=CS1)C2=COC3=CC=CC=C32 Chemical compound COC(=O)CCC(=O)C1=NC(=CS1)C2=COC3=CC=CC=C32 POIABEUHJMTGMB-UHFFFAOYSA-N 0.000 description 2
- DIHULOQPEVWGQV-UHFFFAOYSA-N COC1=C(C=C(C=C1)C2=COC(=C2)C(=O)CCC(=O)O)OC Chemical compound COC1=C(C=C(C=C1)C2=COC(=C2)C(=O)CCC(=O)O)OC DIHULOQPEVWGQV-UHFFFAOYSA-N 0.000 description 2
- RZPYIKRVYSVKIW-UHFFFAOYSA-N COC1=C(C=C(C=C1)C2=COC(=C2)C(=O)CCC(=O)OC)OC Chemical compound COC1=C(C=C(C=C1)C2=COC(=C2)C(=O)CCC(=O)OC)OC RZPYIKRVYSVKIW-UHFFFAOYSA-N 0.000 description 2
- DQDVHSPFOKZCEL-UHFFFAOYSA-N COC1=CC2=C(C=C1)NC=C2C3=COC(=C3)C(=O)CCC(=O)O Chemical compound COC1=CC2=C(C=C1)NC=C2C3=COC(=C3)C(=O)CCC(=O)O DQDVHSPFOKZCEL-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
- 208000005243 Chondrosarcoma Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- 101000952099 Homo sapiens Antiviral innate immune response receptor RIG-I Proteins 0.000 description 2
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 2
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 2
- 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 description 2
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 2
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 2
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 2
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 2
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 2
- 102100026720 Interferon beta Human genes 0.000 description 2
- 108090000467 Interferon-beta Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 102000017578 LAG3 Human genes 0.000 description 2
- 101150030213 Lag3 gene Proteins 0.000 description 2
- 206010027145 Melanocytic naevus Diseases 0.000 description 2
- UUIQMZJEGPQKFD-UHFFFAOYSA-N Methyl butyrate Chemical compound CCCC(=O)OC UUIQMZJEGPQKFD-UHFFFAOYSA-N 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 2
- VKHXAGURVGDHDU-UHFFFAOYSA-N NC(CC1=C(C(CCC(O)=O)=O)SC2=C1C=CC=C2)=O Chemical compound NC(CC1=C(C(CCC(O)=O)=O)SC2=C1C=CC=C2)=O VKHXAGURVGDHDU-UHFFFAOYSA-N 0.000 description 2
- 208000009277 Neuroectodermal Tumors Diseases 0.000 description 2
- 208000007256 Nevus Diseases 0.000 description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
- 229940124060 PD-1 antagonist Drugs 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical group [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 206010061332 Paraganglion neoplasm Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 2
- 208000007452 Plasmacytoma Diseases 0.000 description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 201000010208 Seminoma Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000006069 Suzuki reaction reaction Methods 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 2
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 2
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 2
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 2
- 102100024324 Toll-like receptor 3 Human genes 0.000 description 2
- 102100039357 Toll-like receptor 5 Human genes 0.000 description 2
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 2
- 102100033110 Toll-like receptor 8 Human genes 0.000 description 2
- 102100033117 Toll-like receptor 9 Human genes 0.000 description 2
- UAGJZZDMFOTJRN-UHFFFAOYSA-N [1-[(2-methylpropan-2-yl)oxycarbonyl]indol-3-yl]boronic acid Chemical compound C1=CC=C2N(C(=O)OC(C)(C)C)C=C(B(O)O)C2=C1 UAGJZZDMFOTJRN-UHFFFAOYSA-N 0.000 description 2
- 150000008043 acidic salts Chemical class 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 229960000473 altretamine Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 238000011398 antitumor immunotherapy Methods 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
- NHOWLEZFTHYCTP-UHFFFAOYSA-N benzylhydrazine Chemical compound NNCC1=CC=CC=C1 NHOWLEZFTHYCTP-UHFFFAOYSA-N 0.000 description 2
- 229960002938 bexarotene Drugs 0.000 description 2
- 208000026900 bile duct neoplasm Diseases 0.000 description 2
- 201000000053 blastoma Diseases 0.000 description 2
- 229960001561 bleomycin Drugs 0.000 description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 150000001649 bromium compounds Chemical class 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- JDRMYOQETPMYQX-UHFFFAOYSA-N butanedioic acid monomethyl ester Natural products COC(=O)CCC(O)=O JDRMYOQETPMYQX-UHFFFAOYSA-N 0.000 description 2
- XJHCXCQVJFPJIK-UHFFFAOYSA-M caesium fluoride Chemical compound [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 229940022399 cancer vaccine Drugs 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 229960004562 carboplatin Drugs 0.000 description 2
- 229960005243 carmustine Drugs 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 229940125851 compound 27 Drugs 0.000 description 2
- 229940125936 compound 42 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 229940126545 compound 53 Drugs 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 description 2
- 229960000684 cytarabine Drugs 0.000 description 2
- 229960003901 dacarbazine Drugs 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 125000005265 dialkylamine group Chemical group 0.000 description 2
- IYYZUPMFVPLQIF-UHFFFAOYSA-N dibenzothiophene Chemical compound C1=CC=C2C3=CC=CC=C3SC2=C1 IYYZUPMFVPLQIF-UHFFFAOYSA-N 0.000 description 2
- YNHIGQDRGKUECZ-UHFFFAOYSA-N dichloropalladium;triphenylphosphanium Chemical compound Cl[Pd]Cl.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-N 0.000 description 2
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 230000007783 downstream signaling Effects 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 201000008184 embryoma Diseases 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- FJKIXWOMBXYWOQ-UHFFFAOYSA-N ethenoxyethane Chemical compound CCOC=C FJKIXWOMBXYWOQ-UHFFFAOYSA-N 0.000 description 2
- 201000009123 extragonadal germ cell cancer Diseases 0.000 description 2
- 208000024519 eye neoplasm Diseases 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- CNUDBTRUORMMPA-UHFFFAOYSA-N formylthiophene Chemical compound O=CC1=CC=CS1 CNUDBTRUORMMPA-UHFFFAOYSA-N 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000009499 grossing Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 2
- 150000004677 hydrates Chemical group 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 229960001101 ifosfamide Drugs 0.000 description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000005917 in vivo anti-tumor Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 150000004694 iodide salts Chemical class 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- 229960002247 lomustine Drugs 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 229960004961 mechlorethamine Drugs 0.000 description 2
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 2
- 229960001924 melphalan Drugs 0.000 description 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 2
- 206010027191 meningioma Diseases 0.000 description 2
- 208000037819 metastatic cancer Diseases 0.000 description 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- MKIJJIMOAABWGF-UHFFFAOYSA-N methyl 2-sulfanylacetate Chemical compound COC(=O)CS MKIJJIMOAABWGF-UHFFFAOYSA-N 0.000 description 2
- RFKZTRNQWFVBEH-UHFFFAOYSA-N methyl 3-(4-bromothiophen-2-yl)-3-oxopropanoate Chemical compound COC(=O)CC(=O)C1=CC(Br)=CS1 RFKZTRNQWFVBEH-UHFFFAOYSA-N 0.000 description 2
- YPYBIPWJLZMOOS-UHFFFAOYSA-N methyl 4-(5-chlorothiophen-2-yl)-4-oxobutanoate Chemical compound COC(=O)CCC(=O)C1=CC=C(Cl)S1 YPYBIPWJLZMOOS-UHFFFAOYSA-N 0.000 description 2
- MCJOECNOUKIFNV-UHFFFAOYSA-N methyl 4-(5-methylthiophen-2-yl)-4-oxobutanoate Chemical compound COC(=O)CCC(=O)C1=CC=C(C)S1 MCJOECNOUKIFNV-UHFFFAOYSA-N 0.000 description 2
- WOIOEHSFRAGWFF-UHFFFAOYSA-N methyl 4-bromo-3-fluorothiophene-2-carboxylate Chemical compound COC(=O)C=1SC=C(Br)C=1F WOIOEHSFRAGWFF-UHFFFAOYSA-N 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 201000005962 mycosis fungoides Diseases 0.000 description 2
- YCJZWBZJSYLMPB-UHFFFAOYSA-N n-(2-chloropyrimidin-4-yl)-2,5-dimethyl-1-phenylimidazole-4-carboxamide Chemical compound CC=1N(C=2C=CC=CC=2)C(C)=NC=1C(=O)NC1=CC=NC(Cl)=N1 YCJZWBZJSYLMPB-UHFFFAOYSA-N 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 229960003301 nivolumab Drugs 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 206010073131 oligoastrocytoma Diseases 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 235000019629 palatability Nutrition 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 208000029211 papillomatosis Diseases 0.000 description 2
- 208000007312 paraganglioma Diseases 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 159000000001 potassium salts Chemical class 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical class [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- HVLILIWVZXFTEM-UHFFFAOYSA-N tert-butyl 3-bromo-5-cyanoindole-1-carboxylate Chemical compound N#CC1=CC=C2N(C(=O)OC(C)(C)C)C=C(Br)C2=C1 HVLILIWVZXFTEM-UHFFFAOYSA-N 0.000 description 2
- KNJAOVKFMVMDDF-UHFFFAOYSA-N tert-butyl 3-bromo-5-fluoroindole-1-carboxylate Chemical compound FC1=CC=C2N(C(=O)OC(C)(C)C)C=C(Br)C2=C1 KNJAOVKFMVMDDF-UHFFFAOYSA-N 0.000 description 2
- BZZPVBVOSNRGHB-UHFFFAOYSA-N tert-butyl 3-bromo-6-chloroindole-1-carboxylate Chemical compound C1=C(Cl)C=C2N(C(=O)OC(C)(C)C)C=C(Br)C2=C1 BZZPVBVOSNRGHB-UHFFFAOYSA-N 0.000 description 2
- MAERWTKKEZHNEC-UHFFFAOYSA-N tert-butyl 3-bromo-6-fluoroindole-1-carboxylate Chemical compound C1=C(F)C=C2N(C(=O)OC(C)(C)C)C=C(Br)C2=C1 MAERWTKKEZHNEC-UHFFFAOYSA-N 0.000 description 2
- HWVFAXLKBJQDMB-UHFFFAOYSA-N tert-butyl 4-fluoroindole-1-carboxylate Chemical compound C1=CC=C2N(C(=O)OC(C)(C)C)C=CC2=C1F HWVFAXLKBJQDMB-UHFFFAOYSA-N 0.000 description 2
- PCZRVRIBJPHEBB-UHFFFAOYSA-N tert-butyl 5-fluoroindole-1-carboxylate Chemical compound FC1=CC=C2N(C(=O)OC(C)(C)C)C=CC2=C1 PCZRVRIBJPHEBB-UHFFFAOYSA-N 0.000 description 2
- UEXNCLFRKGJYDV-UHFFFAOYSA-N tert-butyl 6-chloroindole-1-carboxylate Chemical compound C1=C(Cl)C=C2N(C(=O)OC(C)(C)C)C=CC2=C1 UEXNCLFRKGJYDV-UHFFFAOYSA-N 0.000 description 2
- LYXBMZGDRBLUQT-UHFFFAOYSA-N tert-butyl 7-fluoroindole-1-carboxylate Chemical compound C1=CC(F)=C2N(C(=O)OC(C)(C)C)C=CC2=C1 LYXBMZGDRBLUQT-UHFFFAOYSA-N 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 description 2
- SMZMHUCIDGHERP-UHFFFAOYSA-N thieno[2,3-b]pyridine Chemical compound C1=CN=C2SC=CC2=C1 SMZMHUCIDGHERP-UHFFFAOYSA-N 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 229960001196 thiotepa Drugs 0.000 description 2
- 208000008732 thymoma Diseases 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229940044655 toll-like receptor 9 agonist Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 229910052721 tungsten Inorganic materials 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 230000006444 vascular growth Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- WCWUXEGQKLTGDX-LLVKDONJSA-N (2R)-1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methyl-6-pyrrolo[2,1-f][1,2,4]triazinyl]oxy]-2-propanol Chemical compound C1=C2NC(C)=CC2=C(F)C(OC2=NC=NN3C=C(C(=C32)C)OC[C@H](O)C)=C1 WCWUXEGQKLTGDX-LLVKDONJSA-N 0.000 description 1
- RGHNJXZEOKUKBD-NRXMZTRTSA-N (2r,3r,4r,5s)-2,3,4,5,6-pentahydroxyhexanoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-NRXMZTRTSA-N 0.000 description 1
- RIBSTTPRQPAXRS-UHFFFAOYSA-N (5-formylfuran-3-yl)boronic acid Chemical compound OB(O)C1=COC(C=O)=C1 RIBSTTPRQPAXRS-UHFFFAOYSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- XHTYQFMRBQUCPX-UHFFFAOYSA-N 1,1,3,3-tetramethoxypropane Chemical compound COC(OC)CC(OC)OC XHTYQFMRBQUCPX-UHFFFAOYSA-N 0.000 description 1
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 1
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 description 1
- QVANIYYVZZLQJP-UHFFFAOYSA-N 1-benzothiophen-3-ylboronic acid Chemical compound C1=CC=C2C(B(O)O)=CSC2=C1 QVANIYYVZZLQJP-UHFFFAOYSA-N 0.000 description 1
- IIASCQBFNHWZBE-UHFFFAOYSA-N 1-bromoethyl acetate Chemical compound CC(Br)OC(C)=O IIASCQBFNHWZBE-UHFFFAOYSA-N 0.000 description 1
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical class CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- VUQPJRPDRDVQMN-UHFFFAOYSA-N 1-chlorooctadecane Chemical class CCCCCCCCCCCCCCCCCCCl VUQPJRPDRDVQMN-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- ROZCIVXTLACYNY-UHFFFAOYSA-N 2,3,4,5,6-pentafluoro-n-(3-fluoro-4-methoxyphenyl)benzenesulfonamide Chemical compound C1=C(F)C(OC)=CC=C1NS(=O)(=O)C1=C(F)C(F)=C(F)C(F)=C1F ROZCIVXTLACYNY-UHFFFAOYSA-N 0.000 description 1
- XIRRDAWDNHRRLB-UHFFFAOYSA-N 2,6-dibromoaniline Chemical compound NC1=C(Br)C=CC=C1Br XIRRDAWDNHRRLB-UHFFFAOYSA-N 0.000 description 1
- LILXDMFJXYAKMK-UHFFFAOYSA-N 2-bromo-1,1-diethoxyethane Chemical compound CCOC(CBr)OCC LILXDMFJXYAKMK-UHFFFAOYSA-N 0.000 description 1
- VADKRMSMGWJZCF-UHFFFAOYSA-N 2-bromophenol Chemical compound OC1=CC=CC=C1Br VADKRMSMGWJZCF-UHFFFAOYSA-N 0.000 description 1
- TUCRZHGAIRVWTI-UHFFFAOYSA-N 2-bromothiophene Chemical compound BrC1=CC=CS1 TUCRZHGAIRVWTI-UHFFFAOYSA-N 0.000 description 1
- JIZRGGUCOQKGQD-UHFFFAOYSA-N 2-nitrothiophene Chemical compound [O-][N+](=O)C1=CC=CS1 JIZRGGUCOQKGQD-UHFFFAOYSA-N 0.000 description 1
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical class BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
- ILQGHVXNYGLZSR-UHFFFAOYSA-N 2-thiophen-3-ylthiophene Chemical compound C1=CSC(C2=CSC=C2)=C1 ILQGHVXNYGLZSR-UHFFFAOYSA-N 0.000 description 1
- ZBNAIRILIJMDEE-UHFFFAOYSA-N 3,4-dibromofuran Chemical compound BrC1=COC=C1Br ZBNAIRILIJMDEE-UHFFFAOYSA-N 0.000 description 1
- WPBYVMDYYFWYAY-UHFFFAOYSA-N 3,5-dibromopyridine-4-carbaldehyde Chemical compound BrC1=CN=CC(Br)=C1C=O WPBYVMDYYFWYAY-UHFFFAOYSA-N 0.000 description 1
- YMXIIVIQLHYKOT-UHFFFAOYSA-N 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline Chemical group O1C(C)(C)C(C)(C)OB1C1=CC=CC(N)=C1 YMXIIVIQLHYKOT-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- QUBJDMPBDURTJT-UHFFFAOYSA-N 3-chlorothiophene Chemical compound ClC=1C=CSC=1 QUBJDMPBDURTJT-UHFFFAOYSA-N 0.000 description 1
- NWDHTEIVMDYWQJ-UHFFFAOYSA-N 3-fluoro-2-hydroxybenzaldehyde Chemical compound OC1=C(F)C=CC=C1C=O NWDHTEIVMDYWQJ-UHFFFAOYSA-N 0.000 description 1
- UDKYMMQGPNFWDA-UHFFFAOYSA-N 3-iodo-2h-indazole Chemical compound C1=CC=CC2=C(I)NN=C21 UDKYMMQGPNFWDA-UHFFFAOYSA-N 0.000 description 1
- QPBSEYFVZDMBFW-UHFFFAOYSA-N 4-bromo-1-benzothiophene Chemical compound BrC1=CC=CC2=C1C=CS2 QPBSEYFVZDMBFW-UHFFFAOYSA-N 0.000 description 1
- ZHKGAOGJPCWIAF-UHFFFAOYSA-N 4-bromo-3-fluorothiophene-2-carboxylic acid Chemical compound BrC=1C(=C(SC=1)C(=O)O)F ZHKGAOGJPCWIAF-UHFFFAOYSA-N 0.000 description 1
- MRGBBKQOSUHKPF-UHFFFAOYSA-N 4-bromofuran-2-carbaldehyde Chemical compound BrC1=COC(C=O)=C1 MRGBBKQOSUHKPF-UHFFFAOYSA-N 0.000 description 1
- QALYBHRYGIXHOF-UHFFFAOYSA-N 4-bromofuran-2-carboxylic acid Chemical compound OC(=O)C1=CC(Br)=CO1 QALYBHRYGIXHOF-UHFFFAOYSA-N 0.000 description 1
- BGKJZKJDJZNFMI-UHFFFAOYSA-N 4-bromothieno[2,3-c]pyridine-2-carboxylic acid Chemical compound C1=NC=C2SC(C(=O)O)=CC2=C1Br BGKJZKJDJZNFMI-UHFFFAOYSA-N 0.000 description 1
- PDONIKHDXYHTLS-UHFFFAOYSA-N 4-bromothiophene-2-carbaldehyde Chemical compound BrC1=CSC(C=O)=C1 PDONIKHDXYHTLS-UHFFFAOYSA-N 0.000 description 1
- KWWCXEXKKYYNRF-UHFFFAOYSA-N 4-methoxy-4-oxobutanoic acid;hydrochloride Chemical compound Cl.COC(=O)CCC(O)=O KWWCXEXKKYYNRF-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- MUNCFYFZUDHPAG-UHFFFAOYSA-N 6-fluoro-1-benzofuran Chemical compound FC1=CC=C2C=COC2=C1 MUNCFYFZUDHPAG-UHFFFAOYSA-N 0.000 description 1
- YYFFEPUCAKVRJX-UHFFFAOYSA-N 6-fluoro-1h-indole Chemical compound FC1=CC=C2C=CNC2=C1 YYFFEPUCAKVRJX-UHFFFAOYSA-N 0.000 description 1
- KABRXLINDSPGDF-UHFFFAOYSA-N 7-bromoisoquinoline Chemical compound C1=CN=CC2=CC(Br)=CC=C21 KABRXLINDSPGDF-UHFFFAOYSA-N 0.000 description 1
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000036764 Adenocarcinoma of the esophagus Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 206010073358 Anal squamous cell carcinoma Diseases 0.000 description 1
- 206010073127 Anaplastic meningioma Diseases 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 description 1
- 101710127675 Antiviral innate immune response receptor RIG-I Proteins 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 101100452478 Arabidopsis thaliana DHAD gene Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 206010060971 Astrocytoma malignant Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 206010006143 Brain stem glioma Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- MYFOGMUVFPFYPJ-UHFFFAOYSA-N C1=C(SC2=C1OC=C2Br)C(=O)O Chemical compound C1=C(SC2=C1OC=C2Br)C(=O)O MYFOGMUVFPFYPJ-UHFFFAOYSA-N 0.000 description 1
- ZTCLTANEFJWHOZ-UHFFFAOYSA-N C1=CC(=C2C(=C1)NN=C2N)C3=CSC(=C3)C(=O)CCC(=O)O Chemical compound C1=CC(=C2C(=C1)NN=C2N)C3=CSC(=C3)C(=O)CCC(=O)O ZTCLTANEFJWHOZ-UHFFFAOYSA-N 0.000 description 1
- ROXRCHGLZNSACC-UHFFFAOYSA-N C1=CC(=C2C=CSC2=C1)C3=CC=C(S3)C(=O)CCC(=O)O Chemical compound C1=CC(=C2C=CSC2=C1)C3=CC=C(S3)C(=O)CCC(=O)O ROXRCHGLZNSACC-UHFFFAOYSA-N 0.000 description 1
- UJUXCCSNTNDJPG-UHFFFAOYSA-N C1=CC(=C2C=CSC2=C1)C3=CSC(=C3)C(=O)CCC(=O)O Chemical compound C1=CC(=C2C=CSC2=C1)C3=CSC(=C3)C(=O)CCC(=O)O UJUXCCSNTNDJPG-UHFFFAOYSA-N 0.000 description 1
- PRTIVIVQSRMNDY-UHFFFAOYSA-N C1=CC2=C(C=C1F)OC=C2C3=COC(=C3)C(=O)CCC(=O)O Chemical compound C1=CC2=C(C=C1F)OC=C2C3=COC(=C3)C(=O)CCC(=O)O PRTIVIVQSRMNDY-UHFFFAOYSA-N 0.000 description 1
- SHWVSURHVQQJQI-UHFFFAOYSA-N C1=CC2=NC=C(N2C=C1)C3=COC(=C3)C(=O)CCC(=O)O Chemical compound C1=CC2=NC=C(N2C=C1)C3=COC(=C3)C(=O)CCC(=O)O SHWVSURHVQQJQI-UHFFFAOYSA-N 0.000 description 1
- WZIARBNVUQGMGT-UHFFFAOYSA-N C1=CC2=NC=C(N2C=C1)C3=COC(=C3)C=O Chemical compound C1=CC2=NC=C(N2C=C1)C3=COC(=C3)C=O WZIARBNVUQGMGT-UHFFFAOYSA-N 0.000 description 1
- PYGUSYACCHWLIO-UHFFFAOYSA-N C1=CC=C2C(=C1)C(=CN2)C3=CSC(=C3)C(=O)CCC(=O)NO Chemical compound C1=CC=C2C(=C1)C(=CN2)C3=CSC(=C3)C(=O)CCC(=O)NO PYGUSYACCHWLIO-UHFFFAOYSA-N 0.000 description 1
- CNUJBMSMKGAZNS-UHFFFAOYSA-N C1=CC=C2C(=C1)C(=CS2)C3=CC=C(S3)C(=O)CCC(=O)O Chemical compound C1=CC=C2C(=C1)C(=CS2)C3=CC=C(S3)C(=O)CCC(=O)O CNUJBMSMKGAZNS-UHFFFAOYSA-N 0.000 description 1
- LCAYAQHFALXDQP-UHFFFAOYSA-N C1=CC=C2C(=C1)C(=CS2)C3=CSC(=C3)C(=O)CCC(=O)O Chemical compound C1=CC=C2C(=C1)C(=CS2)C3=CSC(=C3)C(=O)CCC(=O)O LCAYAQHFALXDQP-UHFFFAOYSA-N 0.000 description 1
- OUXPHHGQOQAZFU-UHFFFAOYSA-N C1=CC=C2C(=C1)C(=NN2)C3=CSC(=C3)C(=O)CCC(=O)O Chemical compound C1=CC=C2C(=C1)C(=NN2)C3=CSC(=C3)C(=O)CCC(=O)O OUXPHHGQOQAZFU-UHFFFAOYSA-N 0.000 description 1
- RAXKOQKZWJQXHU-UHFFFAOYSA-N C1=CC=C2C(=C1)C3=C(S2)C(=CC=C3)C4=CSC(=C4)C(=O)CCC(=O)O Chemical compound C1=CC=C2C(=C1)C3=C(S2)C(=CC=C3)C4=CSC(=C4)C(=O)CCC(=O)O RAXKOQKZWJQXHU-UHFFFAOYSA-N 0.000 description 1
- UAPVVFWIBOVQRK-UHFFFAOYSA-N C1=CN=C2C(=C1C3=CSC(=C3)C(=O)CCC(=O)O)C=CS2 Chemical compound C1=CN=C2C(=C1C3=CSC(=C3)C(=O)CCC(=O)O)C=CS2 UAPVVFWIBOVQRK-UHFFFAOYSA-N 0.000 description 1
- GISOXRQSQLJIMX-UHFFFAOYSA-N C1=CN=CC2=C1C(=CO2)C3=COC(=C3)C(=O)CCC(=O)O Chemical compound C1=CN=CC2=C1C(=CO2)C3=COC(=C3)C(=O)CCC(=O)O GISOXRQSQLJIMX-UHFFFAOYSA-N 0.000 description 1
- NPPNOVCAJIPPRO-UHFFFAOYSA-N C1=CSC2=C1OC=C2C3=CSC(=C3)C(=O)CCC(=O)O Chemical compound C1=CSC2=C1OC=C2C3=CSC(=C3)C(=O)CCC(=O)O NPPNOVCAJIPPRO-UHFFFAOYSA-N 0.000 description 1
- 125000005915 C6-C14 aryl group Chemical group 0.000 description 1
- FKIHRMDOBAEDEW-UHFFFAOYSA-N CC(CC(C1=CC(C2=CNC3=NC=CC=C23)=CO1)=O)C(O)=O Chemical compound CC(CC(C1=CC(C2=CNC3=NC=CC=C23)=CO1)=O)C(O)=O FKIHRMDOBAEDEW-UHFFFAOYSA-N 0.000 description 1
- AVZVOGWFQKEAKR-UHFFFAOYSA-N CC1=C(C2=CC=CC=C2S1)C3=CSC(=C3)C(=O)CCC(=O)O Chemical compound CC1=C(C2=CC=CC=C2S1)C3=CSC(=C3)C(=O)CCC(=O)O AVZVOGWFQKEAKR-UHFFFAOYSA-N 0.000 description 1
- AAWYNLZWHUXTFE-UHFFFAOYSA-N CC1=C(C2=CC=CC=C2S1)C3=CSC(=C3)C(=O)CCC(=O)OC Chemical compound CC1=C(C2=CC=CC=C2S1)C3=CSC(=C3)C(=O)CCC(=O)OC AAWYNLZWHUXTFE-UHFFFAOYSA-N 0.000 description 1
- AEXFETJZPDXSOR-UHFFFAOYSA-N CC1=C(C=C(S1)C(=O)CCC(=O)O)C2=CSC3=CC=CC=C32 Chemical compound CC1=C(C=C(S1)C(=O)CCC(=O)O)C2=CSC3=CC=CC=C32 AEXFETJZPDXSOR-UHFFFAOYSA-N 0.000 description 1
- XDVGERPKDKTBMK-UHFFFAOYSA-N CC1=C(C=C(S1)C(=O)CCC(=O)OC)C2=CSC3=CC=CC=C32 Chemical compound CC1=C(C=C(S1)C(=O)CCC(=O)OC)C2=CSC3=CC=CC=C32 XDVGERPKDKTBMK-UHFFFAOYSA-N 0.000 description 1
- UBTZGMFBUFZSDV-UHFFFAOYSA-N CCCCOC(=O)C(C)CC(=O)C1=CC(=CO1)Br Chemical compound CCCCOC(=O)C(C)CC(=O)C1=CC(=CO1)Br UBTZGMFBUFZSDV-UHFFFAOYSA-N 0.000 description 1
- XPUWRHSSMUXFOG-UHFFFAOYSA-N CCOC(=O)CC1=C(SC2=CC=CC=C21)Br Chemical compound CCOC(=O)CC1=C(SC2=CC=CC=C21)Br XPUWRHSSMUXFOG-UHFFFAOYSA-N 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 1
- DPOUQIAXRPQLHD-UHFFFAOYSA-N COC(=O)CCC(=O)C1=CC(=CO1)C2=C3C=CNC3=CC=C2 Chemical compound COC(=O)CCC(=O)C1=CC(=CO1)C2=C3C=CNC3=CC=C2 DPOUQIAXRPQLHD-UHFFFAOYSA-N 0.000 description 1
- LFKVRSSCKJBJIF-UHFFFAOYSA-N COC(=O)CCC(=O)C1=CC(=CO1)C2=CN=C3N2C=CC=C3 Chemical compound COC(=O)CCC(=O)C1=CC(=CO1)C2=CN=C3N2C=CC=C3 LFKVRSSCKJBJIF-UHFFFAOYSA-N 0.000 description 1
- NYSJUGDOBZGOCX-UHFFFAOYSA-N COC(=O)CCC(=O)C1=CC(=CO1)C2=CNC3=CC=CC=C32 Chemical compound COC(=O)CCC(=O)C1=CC(=CO1)C2=CNC3=CC=CC=C32 NYSJUGDOBZGOCX-UHFFFAOYSA-N 0.000 description 1
- YLQXWCDWTFDJQU-UHFFFAOYSA-N COC(=O)CCC(=O)C1=CC(=CS1)C2=C3C=CSC3=CC=C2 Chemical compound COC(=O)CCC(=O)C1=CC(=CS1)C2=C3C=CSC3=CC=C2 YLQXWCDWTFDJQU-UHFFFAOYSA-N 0.000 description 1
- RKPPQXLZNTXJSH-UHFFFAOYSA-N COC(=O)CCC(=O)C1=CC(=CS1)C2=CNC3=C2C=CC=C3F Chemical compound COC(=O)CCC(=O)C1=CC(=CS1)C2=CNC3=C2C=CC=C3F RKPPQXLZNTXJSH-UHFFFAOYSA-N 0.000 description 1
- JRXICSJOFKMLGF-UHFFFAOYSA-N COC(=O)CCC(=O)C1=CC(=CS1)C2=COC3=C2SC=C3 Chemical compound COC(=O)CCC(=O)C1=CC(=CS1)C2=COC3=C2SC=C3 JRXICSJOFKMLGF-UHFFFAOYSA-N 0.000 description 1
- DKMOXXSYAQNPDT-UHFFFAOYSA-N COC(=O)CCC(=O)C1=CC(=CS1)C2=CSC3=CC=CC=C32 Chemical compound COC(=O)CCC(=O)C1=CC(=CS1)C2=CSC3=CC=CC=C32 DKMOXXSYAQNPDT-UHFFFAOYSA-N 0.000 description 1
- OOPRFMCUGYXBFS-UHFFFAOYSA-N COC(=O)CCC(=O)C1=CC=C(S1)C2=C3C=CSC3=CC=C2 Chemical compound COC(=O)CCC(=O)C1=CC=C(S1)C2=C3C=CSC3=CC=C2 OOPRFMCUGYXBFS-UHFFFAOYSA-N 0.000 description 1
- HOVOEDKBASPUCM-UHFFFAOYSA-N COC(=O)CCC(=O)C1=CC=C(S1)C2=CSC3=CC=CC=C32 Chemical compound COC(=O)CCC(=O)C1=CC=C(S1)C2=CSC3=CC=CC=C32 HOVOEDKBASPUCM-UHFFFAOYSA-N 0.000 description 1
- CHNPABNYYXKFOK-UHFFFAOYSA-N COC(CCC(C1=C(CC(N)=O)C(C=CC=C2)=C2S1)=O)=O Chemical compound COC(CCC(C1=C(CC(N)=O)C(C=CC=C2)=C2S1)=O)=O CHNPABNYYXKFOK-UHFFFAOYSA-N 0.000 description 1
- ITZLELCRVLYZMH-UHFFFAOYSA-N COC(CCC(C1=CC(C2=CC=CC3=C2SC2=C3C=CC=C2)=CS1)=O)=O Chemical compound COC(CCC(C1=CC(C2=CC=CC3=C2SC2=C3C=CC=C2)=CS1)=O)=O ITZLELCRVLYZMH-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 201000005262 Chondroma Diseases 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 description 1
- 206010065859 Congenital fibrosarcoma Diseases 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229930188224 Cryptophycin Natural products 0.000 description 1
- 102100021906 Cyclin-O Human genes 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 108010013198 Daptomycin Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 208000021994 Diffuse astrocytoma Diseases 0.000 description 1
- 208000006402 Ductal Carcinoma Diseases 0.000 description 1
- 239000001692 EU approved anti-caking agent Substances 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 241000588698 Erwinia Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- RRSNDVCODIMOFX-MPKOGUQCSA-N Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O Chemical compound Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O RRSNDVCODIMOFX-MPKOGUQCSA-N 0.000 description 1
- 206010016935 Follicular thyroid cancer Diseases 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229930191978 Gibberellin Natural products 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229940124683 HCV polymerase inhibitor Drugs 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 description 1
- 101100407305 Homo sapiens CD274 gene Proteins 0.000 description 1
- 101000897441 Homo sapiens Cyclin-O Proteins 0.000 description 1
- 101001082073 Homo sapiens Interferon-induced helicase C domain-containing protein 1 Proteins 0.000 description 1
- 101100407307 Homo sapiens PDCD1LG2 gene Proteins 0.000 description 1
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 description 1
- 101000763579 Homo sapiens Toll-like receptor 1 Proteins 0.000 description 1
- 101000669406 Homo sapiens Toll-like receptor 6 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102100027353 Interferon-induced helicase C domain-containing protein 1 Human genes 0.000 description 1
- 206010061252 Intraocular melanoma Diseases 0.000 description 1
- 208000009164 Islet Cell Adenoma Diseases 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 206010023856 Laryngeal squamous cell carcinoma Diseases 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 206010062038 Lip neoplasm Diseases 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000004059 Male Breast Neoplasms Diseases 0.000 description 1
- 206010025557 Malignant fibrous histiocytoma of bone Diseases 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000009018 Medullary thyroid cancer Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- HDJLSECJEQSPKW-UHFFFAOYSA-N Methyl 2-Furancarboxylate Chemical compound COC(=O)C1=CC=CO1 HDJLSECJEQSPKW-UHFFFAOYSA-N 0.000 description 1
- NMMIHXMBOZYNET-UHFFFAOYSA-N Methyl picolinate Chemical compound COC(=O)C1=CC=CC=N1 NMMIHXMBOZYNET-UHFFFAOYSA-N 0.000 description 1
- 102100023727 Mitochondrial antiviral-signaling protein Human genes 0.000 description 1
- 101710142315 Mitochondrial antiviral-signaling protein Proteins 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028767 Nasal sinus cancer Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 101800001020 Non-structural protein 4A Proteins 0.000 description 1
- 101800001014 Non-structural protein 5A Proteins 0.000 description 1
- 206010030137 Oesophageal adenocarcinoma Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010061534 Oesophageal squamous cell carcinoma Diseases 0.000 description 1
- 206010031096 Oropharyngeal cancer Diseases 0.000 description 1
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 206010033701 Papillary thyroid cancer Diseases 0.000 description 1
- 208000003937 Paranasal Sinus Neoplasms Diseases 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 241001440127 Phyllodes Species 0.000 description 1
- 201000007131 Placental site trophoblastic tumor Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 201000008199 Pleuropulmonary blastoma Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 241000220261 Sinapis Species 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 208000036765 Squamous cell carcinoma of the esophagus Diseases 0.000 description 1
- 208000036844 Squamous cell carcinoma of the larynx Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930189330 Streptothricin Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 102100027010 Toll-like receptor 1 Human genes 0.000 description 1
- 102100039387 Toll-like receptor 6 Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 201000005969 Uveal melanoma Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- UVIQSJCZCSLXRZ-UBUQANBQSA-N abiraterone acetate Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CC[C@@H](CC4=CC[C@H]31)OC(=O)C)C=C2C1=CC=CN=C1 UVIQSJCZCSLXRZ-UBUQANBQSA-N 0.000 description 1
- 229960004103 abiraterone acetate Drugs 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000006336 acinar cell carcinoma Diseases 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000020990 adrenal cortex carcinoma Diseases 0.000 description 1
- 208000007128 adrenocortical carcinoma Diseases 0.000 description 1
- 208000030002 adult glioblastoma Diseases 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229960001445 alitretinoin Drugs 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229920000469 amphiphilic block copolymer Polymers 0.000 description 1
- 206010002224 anaplastic astrocytoma Diseases 0.000 description 1
- 208000013938 anaplastic oligoastrocytoma Diseases 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 229960003005 axitinib Drugs 0.000 description 1
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 1
- 229960003644 aztreonam Drugs 0.000 description 1
- 229960002707 bendamustine Drugs 0.000 description 1
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 125000004532 benzofuran-3-yl group Chemical group O1C=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- UBJAHGAUPNGZFF-XOVTVWCYSA-N bms-184476 Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC(C)=O)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)C=3C=CC=CC=3)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OCSC)C(=O)C1=CC=CC=C1 UBJAHGAUPNGZFF-XOVTVWCYSA-N 0.000 description 1
- 208000030224 brain astrocytoma Diseases 0.000 description 1
- 208000024055 brain glioblastoma Diseases 0.000 description 1
- 201000011609 brain glioblastoma multiforme Diseases 0.000 description 1
- 201000005389 breast carcinoma in situ Diseases 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 125000005392 carboxamide group Chemical group NC(=O)* 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 201000007335 cerebellar astrocytoma Diseases 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- OOCUOKHIVGWCTJ-UHFFFAOYSA-N chloromethyl(trimethyl)silane Chemical compound C[Si](C)(C)CCl OOCUOKHIVGWCTJ-UHFFFAOYSA-N 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- BERDEBHAJNAUOM-UHFFFAOYSA-N copper(I) oxide Inorganic materials [Cu]O[Cu] BERDEBHAJNAUOM-UHFFFAOYSA-N 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 108010006226 cryptophycin Proteins 0.000 description 1
- PSNOPSMXOBPNNV-VVCTWANISA-N cryptophycin 1 Chemical compound C1=C(Cl)C(OC)=CC=C1C[C@@H]1C(=O)NC[C@@H](C)C(=O)O[C@@H](CC(C)C)C(=O)O[C@H]([C@H](C)[C@@H]2[C@H](O2)C=2C=CC=CC=2)C/C=C/C(=O)N1 PSNOPSMXOBPNNV-VVCTWANISA-N 0.000 description 1
- PSNOPSMXOBPNNV-UHFFFAOYSA-N cryptophycin-327 Natural products C1=C(Cl)C(OC)=CC=C1CC1C(=O)NCC(C)C(=O)OC(CC(C)C)C(=O)OC(C(C)C2C(O2)C=2C=CC=CC=2)CC=CC(=O)N1 PSNOPSMXOBPNNV-UHFFFAOYSA-N 0.000 description 1
- 229940112669 cuprous oxide Drugs 0.000 description 1
- KRFJLUBVMFXRPN-UHFFFAOYSA-N cuprous oxide Chemical compound [O-2].[Cu+].[Cu+] KRFJLUBVMFXRPN-UHFFFAOYSA-N 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000000000 cycloalkoxy group Chemical group 0.000 description 1
- 125000005366 cycloalkylthio group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical group [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229940094488 cytarabine liposome Drugs 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 108091092330 cytoplasmic RNA Proteins 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- DOAKLVKFURWEDJ-QCMAZARJSA-N daptomycin Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 description 1
- 229960005484 daptomycin Drugs 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 229940070968 depocyt Drugs 0.000 description 1
- 150000008050 dialkyl sulfates Chemical class 0.000 description 1
- LMEDOLJKVASKTP-UHFFFAOYSA-N dibutyl sulfate Chemical class CCCCOS(=O)(=O)OCCCC LMEDOLJKVASKTP-UHFFFAOYSA-N 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- IEJIGPNLZYLLBP-UHFFFAOYSA-N dimethyl carbonate Chemical compound COC(=O)OC IEJIGPNLZYLLBP-UHFFFAOYSA-N 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 description 1
- 229930188854 dolastatin Natural products 0.000 description 1
- 229940075117 droxia Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 229950009791 durvalumab Drugs 0.000 description 1
- 229940087477 ellence Drugs 0.000 description 1
- 230000002121 endocytic effect Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 description 1
- 229960004671 enzalutamide Drugs 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 201000007129 epithelioid trophoblastic tumor Diseases 0.000 description 1
- 208000028653 esophageal adenocarcinoma Diseases 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 208000007276 esophageal squamous cell carcinoma Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960004750 estramustine phosphate Drugs 0.000 description 1
- ADFOJJHRTBFFOF-RBRWEJTLSA-N estramustine phosphate Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 ADFOJJHRTBFFOF-RBRWEJTLSA-N 0.000 description 1
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 1
- CXXSHQCRSFGZFT-UHFFFAOYSA-N ethyl 2-(2-bromothiophen-3-yl)acetate Chemical compound CCOC(=O)CC=1C=CSC=1Br CXXSHQCRSFGZFT-UHFFFAOYSA-N 0.000 description 1
- IRSJDVYTJUCXRV-UHFFFAOYSA-N ethyl 2-bromo-2,2-difluoroacetate Chemical compound CCOC(=O)C(F)(F)Br IRSJDVYTJUCXRV-UHFFFAOYSA-N 0.000 description 1
- LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 1
- 229960000752 etoposide phosphate Drugs 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 201000007741 female breast cancer Diseases 0.000 description 1
- 201000002276 female breast carcinoma Diseases 0.000 description 1
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 1
- 201000001169 fibrillary astrocytoma Diseases 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Substances OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 201000008396 gallbladder adenocarcinoma Diseases 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 1
- 201000004528 gastrointestinal lymphoma Diseases 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 201000007116 gestational trophoblastic neoplasm Diseases 0.000 description 1
- IXORZMNAPKEEDV-UHFFFAOYSA-N gibberellic acid GA3 Natural products OC(=O)C1C2(C3)CC(=C)C3(O)CCC2C2(C=CC3O)C1C3(C)C(=O)O2 IXORZMNAPKEEDV-UHFFFAOYSA-N 0.000 description 1
- 239000003448 gibberellin Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 108700008776 hepatitis C virus NS-5 Proteins 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 201000006866 hypopharynx cancer Diseases 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 229940099279 idamycin Drugs 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 229960002751 imiquimod Drugs 0.000 description 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 108091005434 innate immune receptors Proteins 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 201000007450 intrahepatic cholangiocarcinoma Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 201000008893 intraocular retinoblastoma Diseases 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 201000010985 invasive ductal carcinoma Diseases 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- GYCHYNMREWYSKH-UHFFFAOYSA-L iron(ii) bromide Chemical compound [Fe+2].[Br-].[Br-] GYCHYNMREWYSKH-UHFFFAOYSA-L 0.000 description 1
- 201000002529 islet cell tumor Diseases 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 201000005263 juxtacortical chondroma Diseases 0.000 description 1
- 208000022013 kidney Wilms tumor Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 201000003785 large intestine adenocarcinoma Diseases 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 201000006721 lip cancer Diseases 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- YTJXGDYAEOTOCG-UHFFFAOYSA-N lithium;di(propan-2-yl)azanide;oxolane Chemical compound [Li+].C1CCOC1.CC(C)[N-]C(C)C YTJXGDYAEOTOCG-UHFFFAOYSA-N 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 201000003175 male breast cancer Diseases 0.000 description 1
- 208000010907 male breast carcinoma Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 208000014699 malignant epithelioid mesothelioma Diseases 0.000 description 1
- 201000000289 malignant teratoma Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 208000010658 metastatic prostate carcinoma Diseases 0.000 description 1
- YDCHPLOFQATIDS-UHFFFAOYSA-N methyl 2-bromoacetate Chemical compound COC(=O)CBr YDCHPLOFQATIDS-UHFFFAOYSA-N 0.000 description 1
- UKIUEFZYSXIGPY-UHFFFAOYSA-N methyl 3-fluorothiophene-2-carboxylate Chemical compound COC(=O)C=1SC=CC=1F UKIUEFZYSXIGPY-UHFFFAOYSA-N 0.000 description 1
- REZMNBYKKVGMCD-UHFFFAOYSA-N methyl 4-bromothieno[2,3-c]pyridine-2-carboxylate Chemical compound C1=NC=C2SC(C(=O)OC)=CC2=C1Br REZMNBYKKVGMCD-UHFFFAOYSA-N 0.000 description 1
- JUYVXCGKMCYNBN-UHFFFAOYSA-N methyl 4-hydroxybutanoate Chemical compound COC(=O)CCCO JUYVXCGKMCYNBN-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 1
- 229910000150 monocalcium phosphate Inorganic materials 0.000 description 1
- 235000019691 monocalcium phosphate Nutrition 0.000 description 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- RAHBGWKEPAQNFF-UHFFFAOYSA-N motesanib Chemical compound C=1C=C2C(C)(C)CNC2=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 RAHBGWKEPAQNFF-UHFFFAOYSA-N 0.000 description 1
- 229950003968 motesanib Drugs 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 201000006462 myelodysplastic/myeloproliferative neoplasm Diseases 0.000 description 1
- DAZSWUUAFHBCGE-KRWDZBQOSA-N n-[(2s)-3-methyl-1-oxo-1-pyrrolidin-1-ylbutan-2-yl]-3-phenylpropanamide Chemical compound N([C@@H](C(C)C)C(=O)N1CCCC1)C(=O)CCC1=CC=CC=C1 DAZSWUUAFHBCGE-KRWDZBQOSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-M naphthalene-1-sulfonate Chemical compound C1=CC=C2C(S(=O)(=O)[O-])=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-M 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000007433 nerve pathway Effects 0.000 description 1
- 229960002653 nilutamide Drugs 0.000 description 1
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 201000008106 ocular cancer Diseases 0.000 description 1
- 201000002575 ocular melanoma Diseases 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 201000005443 oral cavity cancer Diseases 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000013110 organic ligand Substances 0.000 description 1
- 201000006958 oropharynx cancer Diseases 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 229940127084 other anti-cancer agent Drugs 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- VMZMNAABQBOLAK-DBILLSOUSA-N pasireotide Chemical compound C([C@H]1C(=O)N2C[C@@H](C[C@H]2C(=O)N[C@H](C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@H](C(N[C@@H](CC=2C=CC(OCC=3C=CC=CC=3)=CC=2)C(=O)N1)=O)CCCCN)C=1C=CC=CC=1)OC(=O)NCCN)C1=CC=CC=C1 VMZMNAABQBOLAK-DBILLSOUSA-N 0.000 description 1
- 229960005415 pasireotide Drugs 0.000 description 1
- 108700017947 pasireotide Proteins 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000003909 pattern recognition Methods 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 1
- 229960005079 pemetrexed Drugs 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 208000024975 periosteal chondroma Diseases 0.000 description 1
- 230000000079 pharmacotherapeutic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 208000010916 pituitary tumor Diseases 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001084 poly(chloroprene) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 229920002721 polycyanoacrylate Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- CASUWPDYGGAUQV-UHFFFAOYSA-M potassium;methanol;hydroxide Chemical compound [OH-].[K+].OC CASUWPDYGGAUQV-UHFFFAOYSA-M 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000001350 reed-sternberg cell Anatomy 0.000 description 1
- 201000003233 renal Wilms' tumor Diseases 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 108010011655 saratin Proteins 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- CQLFBEKRDQMJLZ-UHFFFAOYSA-M silver acetate Chemical compound [Ag+].CC([O-])=O CQLFBEKRDQMJLZ-UHFFFAOYSA-M 0.000 description 1
- 229940071536 silver acetate Drugs 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- NRAUADCLPJTGSF-VLSXYIQESA-N streptothricin F Chemical compound NCCC[C@H](N)CC(=O)N[C@@H]1[C@H](O)[C@@H](OC(N)=O)[C@@H](CO)O[C@H]1\N=C/1N[C@H](C(=O)NC[C@H]2O)[C@@H]2N\1 NRAUADCLPJTGSF-VLSXYIQESA-N 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- UIUJIQZEACWQSV-UHFFFAOYSA-N succinic semialdehyde Chemical compound OC(=O)CCC=O UIUJIQZEACWQSV-UHFFFAOYSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- WMOVHXAZOJBABW-UHFFFAOYSA-N tert-butyl acetate Chemical compound CC(=O)OC(C)(C)C WMOVHXAZOJBABW-UHFFFAOYSA-N 0.000 description 1
- ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000003554 tetrahydropyrrolyl group Chemical group 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 description 1
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 229950007217 tremelimumab Drugs 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 208000025444 tumor of salivary gland Diseases 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 230000014567 type I interferon production Effects 0.000 description 1
- 208000018417 undifferentiated high grade pleomorphic sarcoma of bone Diseases 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 229960005212 vindesine sulfate Drugs 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D333/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/76—Dibenzothiophenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- AIDS & HIV (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明涉及五元杂环氧代羧酸类化合物及其医药用途。具体地,本发明涉及如式(I)所示的化合物、药用盐、前药、水合物、溶剂合物或晶型,也涉及所述化合物的制备方法、包含所述化合物的药物组合物以及其作为I型干扰素的分泌调节剂,尤其是作为STING激动剂,以及在制备预防和/或治疗与I型干扰素相关疾病的药物中的医药用途。
Description
PCT国内申请,说明书已公开。
Claims (15)
- PCT国内申请,权利要求书已公开。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2019110314811 | 2019-10-28 | ||
CN201911031481 | 2019-10-28 | ||
CN202010218170 | 2020-03-25 | ||
CN2020102181702 | 2020-03-25 | ||
PCT/CN2020/123404 WO2021083060A1 (zh) | 2019-10-28 | 2020-10-23 | 五元杂环氧代羧酸类化合物及其医药用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114829357A true CN114829357A (zh) | 2022-07-29 |
Family
ID=75597280
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202080075621.XA Pending CN114829357A (zh) | 2019-10-28 | 2020-10-23 | 五元杂环氧代羧酸类化合物及其医药用途 |
CN202011150391.7A Active CN112724127B (zh) | 2019-10-28 | 2020-10-23 | 五元杂环氧代羧酸类化合物及其医药用途 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011150391.7A Active CN112724127B (zh) | 2019-10-28 | 2020-10-23 | 五元杂环氧代羧酸类化合物及其医药用途 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20230032101A1 (zh) |
EP (1) | EP4053124A1 (zh) |
KR (1) | KR20220100607A (zh) |
CN (2) | CN114829357A (zh) |
AU (1) | AU2020373913B2 (zh) |
BR (1) | BR112022008074A2 (zh) |
CA (1) | CA3156370A1 (zh) |
MX (1) | MX2022005187A (zh) |
WO (1) | WO2021083060A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113264917B (zh) * | 2021-05-28 | 2022-07-01 | 华南理工大学 | 一种抗乙肝病毒化合物及其制备方法和应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110036001A (zh) * | 2016-10-04 | 2019-07-19 | 默沙东公司 | 作为STING激动剂的苯并[b]噻吩化合物 |
WO2019195124A1 (en) * | 2018-04-03 | 2019-10-10 | Merck Sharp & Dohme Corp. | Benzothiophenes and related compounds as sting agonists |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2730996B1 (fr) * | 1995-02-23 | 1997-06-20 | Adir | Nouveaux composes du thiophene, leur procede de preparation et les compositions pharmaceutiques les renfermant |
CA2329134A1 (en) * | 1998-06-03 | 1999-12-09 | David L. Clark | Hiv integrase inhibitors |
ATE411286T1 (de) * | 1998-12-25 | 2008-10-15 | Shionogi & Co | Aromatische heterocyclen mit hiv integrase inhibierenden eigenschaften |
US6455525B1 (en) * | 1999-11-04 | 2002-09-24 | Cephalon, Inc. | Heterocyclic substituted pyrazolones |
GB0018891D0 (en) | 2000-08-01 | 2000-09-20 | Novartis Ag | Organic compounds |
EP1368458A2 (en) | 2001-02-26 | 2003-12-10 | Pharma Pacific Pty. Ltd. | Interferon-alpha induced gene |
PT2206517T (pt) | 2002-07-03 | 2023-11-07 | Tasuku Honjo | Composições de imunopotenciação contendo anticorpos anti-pd-l1 |
ATE514713T1 (de) | 2002-12-23 | 2011-07-15 | Wyeth Llc | Antikörper gegen pd-1 und ihre verwendung |
US7563869B2 (en) | 2003-01-23 | 2009-07-21 | Ono Pharmaceutical Co., Ltd. | Substance specific to human PD-1 |
DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
CA3201163A1 (en) | 2005-07-01 | 2007-01-11 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
JP2007197324A (ja) * | 2006-01-23 | 2007-08-09 | Toray Ind Inc | 2,4,5−置換−1,3−アゾール誘導体 |
ES2616355T3 (es) | 2007-06-18 | 2017-06-12 | Merck Sharp & Dohme B.V. | Anticuerpos para el receptor humano de muerte programada PD-1 |
WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
EA201170375A1 (ru) | 2008-08-25 | 2012-03-30 | Эмплиммьюн, Инк. | Антагонисты pd-1 и способы их применения |
BRPI0918935A2 (pt) * | 2008-09-18 | 2015-12-01 | Pfizer Ltd | compostos amida úteis em terapia |
HRP20240240T1 (hr) | 2008-12-09 | 2024-04-26 | F. Hoffmann - La Roche Ag | Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice |
JP2013512251A (ja) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Pd−l1/pd−l2の同時阻害 |
KR20190133790A (ko) | 2011-08-01 | 2019-12-03 | 제넨테크, 인크. | Pd-1 축 결합 길항제 및 mek 억제제를 사용하는 암 치료 방법 |
US9988378B2 (en) * | 2012-10-26 | 2018-06-05 | Hoffmann-La Roche Inc. | 1 H-pyrazole and 4,5-disubstituted thiazole inhibitors of SYK |
CN109563081A (zh) * | 2016-04-07 | 2019-04-02 | 葛兰素史克知识产权开发有限公司 | 可用作蛋白调节剂的杂环酰胺类 |
AU2019225919B2 (en) * | 2018-02-21 | 2022-04-21 | The Scripps Research Institute | Agonists of stimulator of interferon genes sting |
US11702430B2 (en) * | 2018-04-03 | 2023-07-18 | Merck Sharp & Dohme Llc | Aza-benzothiophene compounds as STING agonists |
-
2020
- 2020-10-23 AU AU2020373913A patent/AU2020373913B2/en active Active
- 2020-10-23 US US17/772,334 patent/US20230032101A1/en active Pending
- 2020-10-23 KR KR1020227018236A patent/KR20220100607A/ko unknown
- 2020-10-23 WO PCT/CN2020/123404 patent/WO2021083060A1/zh unknown
- 2020-10-23 CN CN202080075621.XA patent/CN114829357A/zh active Pending
- 2020-10-23 MX MX2022005187A patent/MX2022005187A/es unknown
- 2020-10-23 BR BR112022008074A patent/BR112022008074A2/pt not_active Application Discontinuation
- 2020-10-23 CA CA3156370A patent/CA3156370A1/en active Pending
- 2020-10-23 EP EP20881171.1A patent/EP4053124A1/en not_active Withdrawn
- 2020-10-23 CN CN202011150391.7A patent/CN112724127B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110036001A (zh) * | 2016-10-04 | 2019-07-19 | 默沙东公司 | 作为STING激动剂的苯并[b]噻吩化合物 |
WO2019195124A1 (en) * | 2018-04-03 | 2019-10-10 | Merck Sharp & Dohme Corp. | Benzothiophenes and related compounds as sting agonists |
Non-Patent Citations (1)
Title |
---|
SHICHONG PANG等: "《The effect of a \'push-pull\' structure on the turn-on fluorescence of photochromic thio-ketone type diarylethenes》", 《PHOTOCHEMICAL & PHOTOBIOLOGICAL SCIENCES》 * |
Also Published As
Publication number | Publication date |
---|---|
CA3156370A1 (en) | 2021-05-06 |
AU2020373913A1 (en) | 2022-06-02 |
US20230032101A1 (en) | 2023-02-02 |
AU2020373913B2 (en) | 2024-04-18 |
CN112724127A (zh) | 2021-04-30 |
EP4053124A1 (en) | 2022-09-07 |
KR20220100607A (ko) | 2022-07-15 |
WO2021083060A1 (zh) | 2021-05-06 |
MX2022005187A (es) | 2022-07-27 |
BR112022008074A2 (pt) | 2022-07-12 |
CN112724127B (zh) | 2023-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110036001B (zh) | 作为STING激动剂的苯并[b]噻吩化合物 | |
TWI793294B (zh) | Sting促效劑化合物 | |
JP5841531B2 (ja) | フラビウイルス科ウイルスの阻害剤 | |
JP6952695B2 (ja) | インフルエンザウイルス複製の阻害剤、その適用方法および使用 | |
JP2019510802A (ja) | タンパク質調節物質として有用な複素環アミド | |
JP7034162B2 (ja) | インフルエンザウイルス複製の阻害剤及びその使用 | |
TW201134822A (en) | Inhibitors of Flaviviridae viruses | |
TW201200522A (en) | Analogues for the treatment or prevention of flavivirus infections | |
TW201139438A (en) | Analogues for the treatment or prevention of flavivirus infections | |
TW201900179A (zh) | 作為pge2受體調節劑之苯并呋喃及苯并噻吩衍生物 | |
CN112724127B (zh) | 五元杂环氧代羧酸类化合物及其医药用途 | |
JP2013534249A (ja) | フラビウイルス科ウイルス感染の処置または予防のための化合物および方法 | |
CN116284043A (zh) | 三环类化合物及其医药用途 | |
TW202332437A (zh) | 新穎hdac抑制劑及其治療用途 | |
WO2024081311A1 (en) | Cbl-b modulators and uses thereof | |
JP2013531011A (ja) | フラビウイルス感染の処置または予防のための化合物および方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20220729 |